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ABSTRACT
Diabetic skin wound is a common complication of diabetes that occurs in about 15% of diabetic
patients and often requires prolonged hospitalization for its management and treatment. Natural
polymers are used for wound dressing due to their biological adhesiveness, non-toxicity, and
biodegradable nature. 5-Fluorouracil (FU) has been shown to alter adipokine expression which is
implicated in cutaneous wound repair. Thus, our overall objective was to investigate the utility of
chitosan (CS) gel for topical delivery of 5-FU to treat diabetic wounds. We prepared chitosan gel
(2% w/w) in serial dilutions of 5-FU (25μg/mL, 2.5μg/mL, 0.25μg/mL, and 0.025μg/mL) and
evaluated their stability, antimicrobial activity, and rheological properties. Human dermal
fibroblast cells were exposed to each gel formulation under high glucose conditions. MTT, realtime polymerase chain reaction, and cell migration assays were used to determine cell viability,
gene expression, and migration, respectively. We showed that 2% CS gel is stable at both
refrigeration (4-8oC) and room temperatures (20-25oC), and exhibits non-Newtonian flow
property, shear thinning behavior and weak viscoelasticity. At low concentrations (0.025μg/mL),
there is antimicrobial activity of 5-FU against methicillin-resistant Staphylococcus aureus
(MRSA), methicillin-susceptible Staphylococcus aureus (RN1), and at high concentration
(8.0μg/mL) against Escherichia coli. We also found that exposure to CS and 5-FU-CS gel at
different concentrations decreases adipokine gene expression for resistin and PPARγ and
improved cell migration. Our studies suggest CS can be formulated into a hydrogel for topical
delivery, 5-FU-CS gel is potent against pathogenic bacteria found in diabetic wounds and has
therapeutic effect on adipokine gene expression. The findings in this study offer a novel
therapeutic delivery system for 5-FU for diabetic wound healing.
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CHAPTER 1
INTRODUCTION
Diabetes
Diabetes mellitus is a serious disease which is characterized by insufficient production of
insulin by the pancreas or ineffective use of insulin by the body (Fui et al., 2019). Therefore, the
driving factor of diabetes is insulin deficiency. Diabetes is one of the most costly and prevalent
chronic diseases in the United States (Narayan et al., 2003). Pathologically, diabetes can be
classified as either type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM) (Cebeci et
al., 2019), and in some cases as gestational diabetes mellitus (GDM). Etiological studies show
that GDM affects about 5 to 6% of pregnant women and is believed to be an early indicator of
T2DM. T2DM accounts for most cases of diabetes mellitus (~90%), while TIDM accounts for
the remaining cases (~10%) (Guthrie & Guthrie, 2004; Centers for Disease Control and
Prevention, 2020).
Type 1 Diabetes Mellitus
T1DM is a chronic autoimmune disorder in genetically susceptible individuals in which
one’s immune system attacks and destroys pancreatic beta cells (β-cells) resulting in eventual
elimination of insulin production (Fui et al., 2019). Genetically, T1DM can be defined as a
heritable polygenic disease with identical twin concordance of about 30 – 70% (Redondo et al.,
2008), sibling risk of 6 – 7%, and a risk of 1 – 9% for children of a parent with the disease
(Pociot & Lernmark, 2016). Epidemiological data show that T1DM is slightly more common in
males than in females (Diaz-Valencia et al., 2015). Furthermore, studies indicate that incidence
and prevalence of T1DM is gradually on the rise, with an overall annual increase estimated to be
approximately 2 – 3% per year (Mayer-Davis et al., 2017). Even though the cause of diabetes in
1

general is multifactorial, environmental and/or behavioral factors such as infant and adult diet,
vitamin D deficiency, early exposure to islet inflammation associated viruses, and decreased gutmicrobiome diversity have been implicated in the development of T1DM (Rewers &
Ludvigsson, 2016).
Physiologically, these factors are believed to trigger the immune system to attack
pancreatic β-cells, and cause insulin deficiency, which is the underlying factor in diabetes
(Guthrie & Guthrie, 2004; Hull et al., 2017). For example, Greenbaum et al. found that people
who are diagnosed with T1DM have reduced β-cell function compared to a healthy control group
(Greenbaum et al., 2009). Since insulin is a driving factor for anabolic processes in the body, its
deficiency, as seen in all three forms of T1DM, prevents glucose from entering the cells, which
results in its accumulation in the blood. This results in hyperglycemia which causes excess
urination (polyuria), excess thirst (polydipsia), and then excess hunger (polyphagia) because
cells lack fuel (Guthrie & Guthrie, 2004). Despite the abnormalities of β-cell and T1DM, the
methods of managing T1DM continue to improve with administration of insulin still serving as
the main therapeutic approach (DiMeglio et al., 2018).
Type 2 Diabetes Mellitus
T2DM, in contrast, is a complex metabolic disease characterized by defects in insulin
secretion by β-cell or insulin resistance that is mostly related to patients’ lifestyle and dietary
habits (Fui et al., 2019). There are several genes implicated in β-cell action, and in insulin
secretion and activity at the cellular level (Guthrie & Guthrie, 2004). This means a defect in any
of these genes may prevent enzyme production, which eventually blocks the action of insulin.
This disrupts glucose uptake by the cell and increases the breakdown of triglycerides to produce
the metabolic defects associated with T2DM (Cersosimo, 2018; Guthrie & Guthrie, 2004).
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The pathophysiology of T2DM involves an interaction between genetic predisposition
and environmental triggers (Javeed & Matveyenko, 2018; Smushkin & Vella, 2010). Also, the
loss of first-phase insulin release and increased glucagon secretion has been implicated to
accelerate the development of T2DM (Ismail-Beigi, 2012). According to Defronzo, the
pathophysiology of T2DM is mainly driven by the induction of skeletal muscle, hepatic, and
adipose tissue insulin resistance (Defronzo, 2009). Insulin resistance, one of the early defects of
T2DM, is believed to begin many years before the onset of symptoms sufficient for diagnosis.
Many genetic and environmental factors such as age, lifestyle, and obesity (Franks & McCarthy,
2016) have been implicated in the development of insulin resistance in both the peripheral cells
(primarily muscle and fat cells) and the liver (Guthrie & Guthrie, 2004; Lebovitz, 2001). The
development of insulin resistance forces β-cells to increase insulin production to maintain the
blood glucose levels needed for normal physiological processes. However, when this
phenomenon continues over time, then the β-cells begin to fail, either through genetic defects,
glucose toxicity, or depletion, leading to the development of diabetes (Guthrie & Guthrie, 2004).
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WOUND HEALING
Diabetic skin wound is a common complication that occurs in about 15% of diabetic
patients and often requires prolonged hospitalization for its management and treatment (Albert,
2002). For instance, the management of diabetic foot ulceration alone poses a challenging
financial burden on patients and the health system (Al Odhayani et al., 2017). The creation of a
wound involves a disturbance in the cellular, anatomical, and functional epithelial integrity of the
skin due to physical, chemical, thermal, microbial, or immunological insults, which disrupts the
structure and function of the underlying normal tissue (Mekonnen et al., 2013; Oguntibeju,
2019). Thus, wound healing can be defined as an interaction between a complex cascade of
cellular and biochemical activities geared towards the restoration of structural, functional
integrity, and increased strength in an injured tissue (Martin, 1997; Oguntibeju, 2019; Pastar et
al., 2014).
Wounds, in general, can be categorized as either acute or chronic depending on the
severity of the wound. An acute wound heals in a well-organized process with predictable
progress or tissue repair (Demidova-Rice et al., 2012). Conversely, a chronic wound emerges
when the controlled sequence of natural wound healing is delayed and the wound shows no sign
of effective healing, usually within 3 months of tissue injury (Gupta et al., 2017). These wounds
are characterized by excessive levels of pro-inflammatory cytokines, proteases, reactive oxygen
species, formation of drug-resistant microbial biofilms, and deficiency of functional epidermal
cells (Frykberg & Banks, 2015).
Normal Wound Healing
Normal wound healing involves the repair of connective tissue and is typified by four
complex and overlapping phases of hemostasis, inflammation, proliferation, and tissue
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remodeling (Figure 1) (Falanga, 2005; Fui et al., 2019; Gonzalez et al., 2016). The orderly
progression of the healing process is impaired in diabetic patients. For example, in diabetic
patients, slight abrasion or scratch renders one susceptible to the development of chronic
wounds, with an overall impaired healing (Avishai et al., 2017). These complex processes
involve dynamic interactions between different cell types, the extracellular matrix (ECM),
cytokines, and growth factors in distinct phases (Ezhilarasu et al., 2020). These phases of wound
healing usually occur in a time-dependent manner which means any disruption in the process
could potentially lead to a chronic wound or in some cases, pathological scarring (Martin, 1997;
Pastar et al., 2014).
There are four phases that occur during the wound healing process in normal wounds
(Figure 1). The first phase of wound healing that is initiated at the onset of an injury is the
hemostatic phase. During this phase, blood platelets adhere to exposed type 1 collagen, become
activated, and secrete glycoproteins to form platelet aggregation following the injury. Thus,
within minutes of an injury, blood vessels constrict to reduce the extent of hemorrhage allowing
hemostasis to be achieved (Oguntibeju, 2019; Pastar et al., 2014). The inflammation phase has an
overlapping role with the hemostasis phase and is believed to activate the hemostasis
mechanisms that rapidly halt blood loss from the wound. This phase is marked by initial
vasoconstriction and platelet aggregation to initiate blood clotting, followed by vasodilation and
phagocytosis to produce inflammation at the wounded site, which usually takes about two weeks
(Oguntibeju, 2019). Key steps that are involved in the proliferative phase are granulation,
angiogenesis, epithelialization, and contraction of wound edges. Granulation involves the
formation of a collagen bed with the production of new capillaries by fibroblasts. This is
followed by the contraction of wound edges to reduce the defect and an overall formation of new
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epithelial and scar tissues over the wounded site (Fui et al., 2019; Oguntibeju, 2019; Pastar et al.,
2014). The remodeling phase is marked by formation of new collagen with increased tensile
strength due to intermolecular collagen crosslinking. This phase usually lasts anywhere between
21 days to 2 years (Fui et al., 2019; Oguntibeju, 2019).

Figure 1. Four Phases of Wound Healing.
An illustration of four phases of the normal wound healing process. The first phase is represented
by the hemostasis process, inflammation takes place during phase two, proliferation occurs
during phase three and tissue remodeling is the final phase in the wound healing process.
Illustration © 2021 Samuel Tetteh-Quarshie.
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Diabetic Wounds
Diabetic wounds are one of the most severe complications of diabetes mellitus associated
with high morbidity; they are difficult to manage since they are slow to heal and could last for
weeks (Oguntibeju, 2019). The mechanisms responsible for the delay in wound healing in
diabetic patients are not fully understood. Factors such as age, disease state, diet, reactive oxygen
species (Bluher & Mantzoros), and immune state have been implicated in poor wound healing in
diabetic patients (Brem & Tomic-Canic, 2007; Oguntibeju, 2019). Physiologically, a diabetic
wound can be described as a microenvironment characterized by high glucose levels, advanced
glycation end products (AGEs), reactive oxygen species (ROS), and inflammatory cytokines
(Figure 2) (Wang & Graves, 2020). Incidences of high glucose levels have been implicated in
reduced keratinocyte migration and proliferation in both in vivo and in vitro scratch wound
assays (Zhu et al., 2011).
Further studies on diabetic wound healing show that prolonged exposure to high glucose
can result in the loss of endothelial cell integrity which makes the cells susceptible to detachment
and apoptosis (Okonkwo & DiPietro, 2017). Chronic inflammation is also implicated as one of
the most common reasons for delayed wound healing observed in diabetic patients. In this
instance, prolonged elevation of glucose and free fatty acids induce inflammatory processes in
various tissues marked by infiltration of immune cells to tissue sites and the release of proinflammatory markers resulting in tissue damages (Pahwa et al., 2020).
Cutaneous wound healing requires a well-orchestrated interaction of cell migration,
proliferation, and re-epithelialization from different tissues and cells. Thus, any disruption in the
normal functioning of these tissues or cells is catastrophic. Among these cell types, fibroblasts
play critical roles in all phases of wound healing. Following skin abrasion or wounding,
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fibroblasts attracted from the edges of the wound or from the bone marrow produce chemokines
and growth factors that aid in wound healing (Opalenik & Davidson, 2005). For instance, the
expression of basic fibroblast growth factor (bFGF), which is generally high during the late
inflammatory stage, activates macrophages to scavenger pathogens and clear cellular debris (Fui
et al., 2019).
In a clinical study conducted by Matsumoto et al. (2013) patients with diabetic ulcers had
sufficient granulation tissue for skin grafting after applying bFGF-impregnated gelatin sheet for
three weeks. Another cell type that is critical to the wound healing process is macrophages.
Macrophages are an important cell type of the innate immune system and are required for wound
repair. Alterations of the normal functioning of macrophages are implicated in diabetic wounds
(Mirza & Koh, 2011). Phenotypic changes in normal wounds, especially a switch from a
proinflammatory to a pro-reparative phenotype supports tissue regrowth. However, in diabetic
wounds, macrophage deficits result in phenotypes that fail to stimulate tissue repair (Mirza &
Koh, 2011).

Figure 2. Delayed Wound Healing Factors in Diabetic Patients.
Several factors that are implicated in the delayed wound healing process in diabetic patients
include AGEs, ROS and inflammatory cytokines (BioRender, 2021).
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ADIPOKINES AND WOUND HEALING
Wound healing takes place in all three layers of the skin: the epidermis, the dermis, and
the subcutaneous adipose tissue. In the physiological state, adipose tissue plays an important
role, including thermoregulation, protection of internal organs, and steroid hormone production
(Bergmann & Sypniewska, 2013; Bluher, 2013). More so, several studies suggest that adipose
tissue is an active participant in wound repair (Ebrahimian et al., 2009; Kim et al., 2007; Nie et
al., 2011). However, the importance of adipose tissue in wound healing has not been studied
extensively. Adipose tissue is a major endocrine organ that releases multiple bioactive
substances, known as adipose-derived secreted factors or adipokines (Ouchi et al., 2011). Studies
on the relationship between adipose tissue, insulin resistance, and diabetes have created a
crosstalk centered around abnormalities in adipocyte metabolism and their proinflammatory
potential.
Adipokines are defined as a group of bioactive markers secreted by adipose tissue and act
as paracrine and endocrine hormones (Bluher, 2014). Although the full set of human adipokines
is still not entirely characterized, it has become clear that adipose tissue is a source of more than
600 potentially secretory proteins (Lehr et al., 2012). In the last few decades, the role of
adipokines in immune system modulation, inflammation, and metabolic syndrome has generated
an interest in adipokine studies. Examples of some of the diverse functions of adipokines include
regulation of energy expenditure, insulin sensitivity, glucose and lipid metabolism, regulation of
satiety and appetite, regulation of blood pressure, and hemostasis (Table 1) (Francisco et al.,
2019; Gandhi et al., 2010). The ability of these bioactive markers to assume pro-inflammatory
and anti-inflammatory activities make them unique (Ouchi et al., 2011).
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Adipokines

Site of Expression

Functions

Therapeutic Target

Apelin

Adipose tissue, stomach,
heart, lung, skeletal muscle

Regulate cardiovascular and
fluid homeostasis, food
intake etc.
Regulate inflammation,
endothelial dysfunction,
smooth muscle cell
dysfunction etc.
Regulate lipid and glucose
metabolism and fatty acid
oxidation
Regulate lipid and glucose
metabolism
Regulate immunity, neural
development, and lipid
metabolic homeostasis
Regulate glucose
homeostasis, lipid
metabolism and fat mass
Regulate food intake and
maintain metabolic
homeostasis
Regulate lipid metabolism,
cell proliferation, apoptosis
etc.

Metabolic disorder
(obesity and
cardiovascular diseases)
Metabolic syndrome
(insulin resistance and
diabetes)

Resistin
Adiponectin
NAMPT

Adipose tissue, macrophages,
spleen, and bone marrow cells
Adipose tissue, skeletal and
cardiac myocytes, endothelial
cells
visceral adipose tissue, kidney

IL6

Adipose tissue, smooth muscle
cells and macrophages

PPARγ

Adipose tissue, liver, kidney,
heart, and skeletal muscle

Leptin

Adipose tissue, gastric mucosa
tissue

TNFα

Adipose tissue, and
endothelial cells

Metabolic disorder
(obesity and insulin
resistance)
Metabolic syndrome
(diabetic nephropathy)
Cardiac diseases caused
by metabolic disorder
Metabolic disorder
(insulin sensitivity)
Metabolic disorder
(obesity)
Metabolic disorder
(insulin sensitivity and
resistance)

Table 1. List of Various Adipokines.
Table 1 lists examples of a variety of well-known adipokines, where they are expressed, the
major systemic and tissue specific functions for each, and established or potential targets for
therapeutic treatments.
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ADIPOKINES AND OBESITY-RELATED DISEASES
The established relationship between adipokines and obesity-associated diseases such as
T2DM, show that adipokines have an enormous potential for clinical relevance both as bioactive
markers and as therapeutic agents (Bluher, 2014; Timar et al., 2014; Xu et al., 2015). Therefore,
it has been proposed that adipokines could be used to determine disease progression, to monitor
clinical responses to therapeutic and lifestyle interventions, and to monitor treatment adherence
(Bluher et al., 2012). Most importantly, even though the mechanism of regulating molecular and
physiological function has not been clearly elucidated, alterations in adipokine secretion have
been implicated in obesity-related diseases (Fasshauer & Bluher, 2015). For instance, studies
show the molecular mechanisms of insulin activity may be impaired by the induction of chronic
low-grade inflammation in adipose tissue through the synthesis of chemotactic substances that
enhance the influx of lymphocytes and monocytes (Bergmann & Sypniewska, 2013; Lumeng &
Saltiel, 2011). This phenomenon highlights the importance of understanding the effect of
impaired adipokine secretion in the pathogenesis of diabetes-related complications such as
delayed diabetic wound healing.
Resistin
Resistin, an adipocyte-derived polypeptide, is a member of a secretory protein family
commonly known as resistin-like molecules (RELMs). A distinct feature of this family of
proteins is the presence of a highly conserved, cysteine-rich C terminus (Booth et al., 2015;
Cebeci et al., 2019; Pang & Le, 2006). The discovery of resistin is credited to three independent
groups, Kim, Holcomb, and Steppan, who were investigating different aims at the time of this
discovery (Pang & Le, 2006). Resistin was first discovered by Steppan et al. and appeared in a
2001 publication (Steppan et al., 2001). Following its discovery, resistin was first considered to
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mainly be a link between obesity and insulin resistance and shown to be more heavily secreted
by adipocytes in a rodent model (Steppan et al., 2001). Steppan et al. showed in their earlier
studies that this adipokine circulates in the serum of rodents and is increased in both genetic and
diet induced obesity (Steppan et al., 2001). On the other hand, Kim and colleagues identified
resistin via microarray analysis as an adipose tissue-specific secreted factor (Kim et al., 2001).
Holcomb et al. initially identified resistin as an expressed sequence tag database against a related
protein induced during lung inflammation (Guest et al., 2017; Holcomb et al., 2000). They later
referred to this as “found in inflammatory zone 3” (FIZZ3). The expression of resistin has been
identified in several cell types such as adipocytes (Savage et al., 2001; Steppan et al., 2001),
intestinal epithelium, and skeletal muscle cells (Nogueiras et al., 2003), and astrocytes (Morash
et al., 2002). The degree of resistin synthesis varied greatly in these sites. For instance, recent
studies in humans have indicated that unlike rodents, resistin is heavily expressed in peripheral
mononuclear cells, but minimally expressed in adipocytes and preadipocytes (Savage et al.,
2001).
Mouse resistin is an 11 kDa cysteine-rich polypeptide, with its genes located on
chromosome 8, and exclusively is expressed in high levels in white adipose tissue (Pang & Le,
2006). It contains five intramolecular disulfide bonds with multiple β-turns and is synthesized as
a 114 amino acid (aa) precursor (Jamaluddin et al., 2012). Unlike in humans, the mouse RELMs
family is made up of four members: resistin, RELMα, RELMβ and RELMγ (Pang & Le, 2006).
More so, there is a debate about the functional roles of resistin in mouse and humans given some
structural and chromosomal changes. Human resistin is a 12.5 kDa cysteine-rich polypeptide
with a more mature sequence consisting of 108 amino acids (Jamaluddin et al., 2012). Also, the
human resistin gene is located on chromosome 19 with only two identified family members,
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resistin and RELMβ (Pang & Le, 2006). Even though mouse and human resistin gene share
64.4% sequence homology at mRNA level and 59% identity at amino acid level (Steppan &
Lazar, 2004), the genes have divergent promoter regions with different mechanisms of
regulation, tissue distribution, and functions (Ghosh et al., 2003). In humans, the expression of
resistin is not just limited to adipose tissues but it is expressed by other cell populations such as
peripheral blood mononuclear cells, macrophages, and bone marrow cells (Fain et al., 2003;
Patel et al., 2003). It is worth noting while some studies have reported only human preadipocytes
express resistin (Janke et al., 2002), other studies show that mature human adipocytes also
produce insulin (Degawa-Yamauchi et al., 2003).
Following its discovery, several studies have explored the possible relationship between
resistin and metabolic disorders in healthy subjects and diabetic patients. For instance, a study
conducted by Reilly et al in healthy and T2DM patients showed an increased level of resistin in
woman versus men, as well as in T2DM groups versus healthy subjects (Reilly et al., 2005). This
suggests that resistin could be a key predictor of inflammatory and other metabolic disorders
such as arteriosclerosis, obesity and visceral adiposity, insulin resistance, hyperglycemia, and
hypertension. Conversely, one of the early findings by Steppan and colleagues show that
administration of resistin to wildtype mice worsened glucose homeostasis and insulin sensitivity.
However, neutralizing the expression of resistin by injection of antibodies in diet-induced obese
mice decreased blood glucose and improved insulin sensitivity (Steppan et al., 2001).
This initial evidence has led to the speculation that resistin could possibly be one of the
major factors contributing to insulin resistance and its related diseases. The expression of resistin
in immune cells and its ability to infiltrate the adipose tissue (Lehrke et al., 2004) demonstrates
that resistin is likely related to the inflammatory status of an individual. Further studies have also
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explored the expression of resistin in the presence of hormones and different molecules. Among
these, thiazolidinediones (TZDs), insulin, glucose, glucocorticoid, and growth hormone have
been implicated to regulate resistin gene expression (Pang & Le, 2006). Experimental evidence
gathered by Shojima et al. (2002) shows that resistin expression is significantly upregulated by
high glucose concentrations in 3T3-L1 adipocytes. The same study also found that administering
insulin to these adipocytes suppressed expression of resistin mRNA and protein (Shojima et al.,
2002). Apart from its role in insulin resistance and diabetes, increasing evidence suggests resistin
plays a critical role in angiogenesis and endothelial function – key steps in wound healing.
Endothelial cells form the main physical barrier between blood and the arterial wall and
controls the movement of solutes and fluid from the vascular space to the surrounding tissues.
This enables them to release vasoactive and trophic substances such as prostacyclin, endothelium
-derived growth relaxing factor/nitric oxide (NO), and angiotensin II (Caldwell et al., 1976;
Jamaluddin et al., 2012; Moncada et al., 1976). These substances aid in controlling vascular
growth, platelet function, coagulation, and inflammatory responses (Libby, 2001). However,
prolonged exposure to high glucose can result in a loss of endothelial cell integrity, making them
susceptible to detaching and apoptosis (Okonkwo & DiPietro, 2017). When this happens, there is
an alteration in endothelial metabolism and function which eventually affects the angiogenesis
process (Altabas, 2015).
Studies investigating endothelial repair in diabetic patients have identified adipocytes as
one of the factors involved in damaged vascular repair. These cells produce several bioactive
markers that contribute to a chronic inflammatory state by secreting TNF-α, a proinflammatory
adipokine that reduces proliferation of endothelial progenitor cells (Tilg & Moschen, 2008). For
example, recent studies have shown that resistin strongly upregulates IL-6 and TNF-α in human
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peripheral blood mononuclear cells though NF-κβ pathway (Bokarewa et al., 2005). These
preliminary findings highlight the inflammatory effect of resistin on other adipokines and its
overall action of endothelial tissue repair in diabetic patients.
Angiogenesis, formation of new blood vessels, is a complex process which is
characterized by increased vascular permeability, matrix degradation, migration, and
proliferation of endothelial cells (Jamaluddin et al., 2012). As previously established,
angiogenesis is an important physiological pathway, in both normal and diabetic wound healing
process. Experimental evidence by Mu et al. (2006) on human endothelial coronary artery
endothelial cells show that human recombinant resistin stimulates proliferation, stimulates
migration, and enhances capillary-like tube formation. Furthermore, this study reports that
resistin also up-regulates gene expression of critical angiogenesis-promoting factors such as
vascular endothelial growth factor receptors (VEGFR-1 and VEGFR-2) and matrix
metalloproteinase (MMP-1 and MMP-2) (Mu et al., 2006). Growth factors are soluble signaling
proteins whose inhibitory and stimulatory properties during the different stages of normal wound
healing enhance the overall healing process (Fui et al., 2019). Major growth factors that have
been extensively studied in wound healing are platelet-derived growth factors (PDGF), bFGF,
vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) (Fui et al.,
2019). Thus, the ability of resistin to stimulate the expression of these growth factors suggest that
resistin could potentially play a key role in the management and treatment of diabetic wounds.
PPAR-Gamma
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription
factors that regulate genes involved in cellular differentiation and metabolic processes such as
glucose and lipid homeostasis (Janani & Ranjitha Kumari, 2015). PPARs belong to the nuclear
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hormone receptor superfamily, and consist of three isotypes, namely PPAR-α, PPAR-β/δ, and
PPAR-γ (Berger & Moller, 2002; Janani & Ranjitha Kumari, 2015; Michalik et al., 2006). Even
though these isoforms share a high degree of structural homology, such as DNA-binding domain
and ligand cofactor-binding domain with members of the superfamily (Michalik et al., 2006),
they also differ from each other in relation to tissue distribution and physiological roles (Janani
& Ranjitha Kumari, 2015). PPARs have been implicated in the regulation of genes that regulate
homeostasis (Lefebvre et al., 2006), glucose and lipoprotein metabolism (Staels et al., 1998),
fatty acid uptake, oxidation, cell proliferation, and inflammation in vascular tissue formation
(Moraes et al., 2006). The discovery of genes that are regulated by PPARs and their implication
in the pathogenesis of metabolic diseases such as metabolic syndrome, type 2 diabetes mellitus,
nonalcoholic fatty liver disease, and cardiovascular disease (Han et al., 2017) make them
important molecular targets in developing new drugs to treat these complications.
The discovery of PPAR-γ and its role in metabolism has garnered significant scientific
and clinical interest in the last two decades. Unlike human PPAR-α and PPAR-β/δ, which are
localized at chromosome region 6p21.2-21.1 with nine exons (Skogsberg et al., 2000), human
PPAR-γ (also composed of nine exons) is localized on chromosome 3p25 (Fajas et al., 1997).
Adipose tissue is the major site of PPAR-γ expression, and some of the biological functions at
this site include adipose tissue differentiation, insulin sensitivity, lipid storage, glucose
metabolism, and regulation of genes involved in the metabolic process (Han et al., 2017).
Contrary to the high levels of PPAR-γ protein expressed in adipose tissues, the level of
expression seen in liver, skeletal muscle, and heart is usually low-to-moderate. Evidence shows
that under certain physiological conditions, PPAR-γ protein can be significantly upregulated in
these sites. For instance, Park et al. found that PPAR-γ gene expression was upregulated in
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muscle cultures from type 2 diabetic subjects when compared with lean nondiabetic subjects
(Park et al., 1997). Another major site where PPAR-γ is expressed in relatively high levels apart
from adipocytes is vascular cells, such as endothelial cells, smooth muscle cells, and
macrophages (Han et al., 2017). The role of PPAR-γ in vasculature and inflammation has been
extensively studied in the last 20 years. In endothelial cells, PPAR-γ regulates biomarkers and
other molecular targets that are critical to inflammation and atherosclerosis (Marx et al., 2003).
Following the discovery of PPARs, several studies have explored the physiological
characteristics of each isotype in different animal models, especially PPAR-γ isoforms. For
example in mouse, PPAR-γ1 and PPAR-γ2 have been identified, while in humans and nonhuman primates, PPAR-γ4 has also been identified in addition to PPAR-γ1 and PPAR-γ2 (Han et
al., 2017).
Even though the involvement of PPAR-γ in diabetes and obesity has been extensively
studied due to its role in regulating glucose metabolism, its role in wound healing is only
beginning to be explored. It is well established that in skin wound healing, PPAR-α controls the
early inflammation phase of healing (Michalik et al., 2001), PPAR-β regulates keratinocyte
proliferation, adhesion, and migration (Michalik et al., 2001; Tan et al., 2003; Tan et al., 2004),
and PPAR-δ participates in promoting fibroblast proliferation (Li et al., 2012). However, little
has been elucidated about the direct role of PPAR-γ in wound healing. As already eluded to,
macrophages are one of the key immune cells that are recruited to a wounded site after skin
injury, and evidence shows that PPAR-γ is a key contributing factor that aids macrophages to
carry out their inflammatory properties (Mahdavian et al., 2011).
In wound healing, macrophage PPAR-γ signaling is necessary for the effective clearance
of apoptotic cells and the switching from proinflammatory macrophage to anti-inflammatory
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macrophage. Overall, this process is important for resolving inflammation and maintaining tissue
homeostasis (Chen et al., 2015). In addition to its role in enhancing macrophage polarization
during wound healing, PPAR-γ has also been recognized to play an important role in immune
response via its ability to inhibit the expression of inflammatory cytokines and to direct the
differentiation of immune cells towards anti-inflammatory phenotypes (Tyagi et al., 2011). This
transition is important for the regulation of angiogenesis, granulation tissue formation, and
wound closure (Mirza et al., 2009) – key steps in normal wound healing. To further evaluate the
importance of PPAR-γ activity and macrophage wound healing, Chen et al. (2015) found that
macrophage PPAR-γ deficiency (PPAR-γ knock out) mice exhibited impaired skin wound
healing which reduce collagen deposition, angiogenesis, and granulation formation. Therefore,
understanding the physiological role of PPAR-γ activity in diabetic wound healing could
enhance efforts for developing synthetic PPAR-γ agonists to combat diabetic wounds.
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CHAPTER 2
TOPICAL DRUG DELIVERY FORMULATIONS AS POTENTIAL DIABETIC
WOUND HEALING TREATMENTS
As discussed in Chapter 1, wound healing is a multifaceted process that involves four
overlapping phases, namely hemostasis, inflammation, proliferation, and tissue remodeling (see
Figure 1). These mechanisms result in the restoration of anatomical integrity with analogous
function (Patel et al., 2019). Unlike acute wounds which generally heal without complications,
chronic wounds are a result of poor blood circulation, diseases like diabetes, and stressed
environmental conditions (Patel et al., 2019). Furthermore, they are expensive and difficult to
manage. As a result, there is an alarming increase in the incidence of delayed wound healing in
diabetic patients globally. For example, in the United Kingdom alone, a National Health Service
report shows that up to 5 billion pounds were spent on diabetic wound treatment annually (Guest
et al., 2017). Several treatments have been proposed for the management of diabetic wounds, and
these are usually aimed at targeting various phases of the wound healing process (Fui et al.,
2019). Examples of these treatments include customized wound dressing, hyperbaric oxygen,
surgical debridement (Fui et al., 2019), and negative pressure wound therapy (Liu et al., 2017).
Customized wound dressings are used for different types of chronic wounds within 12
weeks of onset, while hyperbaric oxygen and negative pressure are usually used for diabetic
wounds that persist for more than 12 weeks (Fui et al., 2019). Of these therapies, hyperbaric
oxygen therapy (HBOT) has been heavily relied upon in the clinical setting. This therapy
involves placing a patient in an enclosed chamber where the pressure is greater than normal
pressure and supplying them with 100% oxygen. The treatment has been shown to improve
tissue hypoxia, improve vessel perfusion, reduce inflammation, and increase angiogenesis
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(Okonkwo & DiPietro, 2017; Tiaka et al., 2012). Unfortunately, HBOT is expensive and
regardless of its track record in the clinical setting, it still does not provide a complete answer for
treating chronic wounds such as diabetic foot ulceration (Okonkwo & DiPietro, 2017).
Therefore, the high cost of managing diabetic wounds in a clinical setting and the challenges
faced by these specialized treatments have led scientists to explore natural biodegradable
products for therapy. In attempts to improve results in diabetic wound treatment, advanced
therapy such as topical application of growth factors and bioengineered cellular therapies
(Frykberg & Banks, 2015) employing different drug delivery systems are being investigated.
Among these drug delivery systems, chitosan gel has become a focus of attention in ensuring
effective delivery of drugs to the site of action without negative side effects due to its
biodegradable nature.
Chitin
Chitin is a linear polysaccharide, made up of β-(1,4)-linked N-acetyl-d-glucosamine units
and is considered to be one of the macromolecules with highest production rate and
biodegradability existing in nature (Figure 3). Structurally, there are three different polymorphs
of chitin namely, α-chitin, β-chitin, and γ-chitin (Muxika et al., 2017). At the industrial level,
chitin is chemically extracted from marine shell waste streams through methods such as
deproteinization, demineralization, and discoloration (Philibert et al., 2017). After the
discoloration step, chitin is converted to chitosan either through enzymatic or chemical
processes. In most cases, the chemical process is preferred since it is cost effective and suitable
for bulk production (Meyers et al., 1975; Younes & Rinaudo, 2015). The primary chemical
method used in this process is deacetylation. Chemical deacetylation involves the treatment of
chitin with hydroxides at high temperatures, usually above 80°C (Muxika et al., 2017).
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Chitosan
Chitosan, a linear amino polysaccharide, is composed of glucosamine and N-acetyl
glucosamine units and linked by β (1–4) glycosidic bonds (Figure 3) (Aytekin et al., 2011; Dai et
al., 2011; Muxika et al., 2017; Ouyang et al., 2018). As a natural copolymer, chitosan is
commercially derived from chemical deacetylation of crustacean chitin under strong alkali
treatment (Fai et al., 2011; Muxika et al., 2017). The presence of nitrogen in the molecular
structure of chitosan and its cationic nature makes the chitosan polymer distinct from other
polysaccharides (Bhattarai et al., 2010). Chemically, either acids or alkalis can be used to
deacetylate chitin. However, studies show that the glycosidic bonds are very susceptible to acid,
hence alkali deacetylation is most frequently employed for chitosan production (Hajji et al.,
2014; Meyers et al., 1975). Dissolving chitosan in an acidic medium results in protonation of the
amino acid groups in the chain. When this happens, the polymer becomes cationic and then
interacts with different types of molecules (Lizardi-Mendoza et al., 2016). The production of
chitosan through N-deacetylation can either occur homogeneously or heterogeneously (LizardiMendoza et al., 2016). Physicochemical characteristics of chitosan, such as purity, crystallinity,
inorganic matter content, degree acetylation, molecular weight, and water content, among others,
have determinant influences on most of its functional properties (Dornish et al., 2001; LizardiMendoza et al., 2016).
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Figure 3. Chemical Structures of Chitin and Chitosan.
DEGREE OF ACETYLATION AND MOLECULAR WEIGHT
One of the major distinctions between chitin and chitosan is the degree of acetylation
(DA). Chitin deacetylation reaction progresses by exposing amino groups along the molecule.
The proportion of acetylated and deacetylated groups causes several changes in the main
properties of the molecule. Since the amino groups are ionizable, chitosan becomes polycationic
when these amino groups are in acidic pH environments. This unusual quality allows chitosan to
actively interact with diverse molecules in solution. Thus, the DA regulates the solubility, extent
of swelling in water, bioactivity, and biocompatibility nature of chitosan (Lizardi-Mendoza et al.,
2016). The molecular weight of chitosan is a characteristic that has determinant influence in
most of its functional properties. These characteristics have a marked effect on the functional
properties of chitosan either in solution or solid state. The molecular weight has particular
influence on the viscoelastic properties of solutions and hydrated colloidal forms. As with many
other natural polymers, the molecular characteristics of chitosan are polydisperse. In chitosan,
the molecular weight is also a result of depolymerization through the deacetylation process.
Together with the degree of acetylation, molecular weight is the most important chemical
characteristic of chitin and chitosan (Lizardi-Mendoza et al., 2016)
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BIOMEDICAL APPLICATIONS
Biomedical applications of chitosan has been extensively studied and used in diverse
fields such as biomedicine, cosmetology, agriculture, and pharmaceutics, among others (Muxika
et al., 2017), owing to its non-toxic, biodegradable, and biocompatible properties (Philibert et al.,
2017). Clinical application of chitosan includes wound dressing, drug delivery, tissue
engineering, blood anticoagulant, bone regeneration biomaterial, and antimicrobial agent (Anitha
et al., 2014; Azad et al., 2004; Muzzarelli et al., 1999). Chitosan has also been found to enhance
the functions of inflammatory cells such as polymorphonuclear leukocytes, macrophages, and
fibroblasts in promoting granulation and organization (Okamoto et al., 2003). Most importantly,
studies in animal models show that it enhances blood coagulation (Okamoto et al., 2003) and
accelerates wound healing (Kweon et al., 2003). In particular, Okamoto et al. (2003) reported
that chitin and chitosan granules enhanced re-epithelization and regenerated normal skins in open
wounds. As natural polymer and a drug delivery vehicle, chitosan and its derivatives have been
widely used to deliver active ingredients such as drugs, growth factors, stem cells and peptides
(Figure 4) (Bhattarai et al., 2010).
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Figure 4. Utility of Chitosan for Wound Healing.
Diagram of the characteristics of chitosan-based drug formulation and the physiological
applications of chitosan as a delivery vehicle. Chitosan can be used to deliver active substances,
which could promote wound healing.
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CHAPTER 3
DRUG DELIVERY SYSTEMS: EXPLORING RHEOLOGICAL PROPERTIES
AND ANTIMICROBIAL ACTIVITY OF 5-FU CHITOSAN GEL
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ABSTRACT
Background: Topical drug delivery is an attractive method for local and systemic treatments
with many advantages over conventional dosage forms. Formulating drugs as topical gels can
increase residence time of the drug, and improve release of the active ingredients, which
enhances the overall bioavailability of the drug at the site of action. Effectively formulating
topical drugs in gels or creams involves a thorough understanding of their rheological properties.
Thus, the steady, dynamic rheological properties, and antimicrobial potential of chitosan gel
formulated with 5-fluorouracil (5-FU), were explored. Methods: Chitosan gel (2% w/w) was
prepared in serial dilutions of 5-FU. Stability, antimicrobial activities, and rheological properties
such as flow behavior, oscillatory sweep tests (amplitude and frequency), and creep recovery of
gels were analyzed. Results: Each concentration of 5-FU-CS gel demonstrated shear thinning
behavior with a flow index < 1. CS gel formulations displayed weak gel-like properties. Storage
modulus values (G’) were less than loss modulus values (G”). Stability (pH and conductivity)
was maintained after three weeks of storage at 4-8oC and 20-25oC. 5-FU and 5-FU-CS gel
significantly inhibited growth of MRSA and RN1; however, there was no growth inhibition on E.
coli. Drug-free CS gel had no growth inhibition against MRSA, RN1 or E. coli. The MIC for 5FU against MRSA, RN1, and E. coli were 0.5μg/mL, 0.5μg/mL, and 8.0μg/mL, respectively.
Conclusions: CS was formulated into non-Newtonian hydrogel with shear thinning properties.
CS gel was viscous and less elastic. 5-FU-CS gel is stable at both room and cold temperatures
after three weeks of storage. Our data show 5-FU and 5-FU-CS gel have antimicrobial activities
against MRSA and RN1 at low concentrations, and against E. coli at higher concentrations.

26

INTRODUCTION
5-fluorouracil (5-FU) is a uracil analogue that can be converted into three active
metabolites, namely fluorouridine triphosphate, fluorodeoxyuridine triphosphate, and
fluorodeoxyuridine monophosphate via intracellular conversion (Figure 5). 5-FU is used as
chemotherapeutic agent due to its ability to cause alterations in RNA processing/function and
severe DNA damage which results in apoptosis (Longley et al., 2003). Even though 5-FU
remains as one of the first line for chemotherapy treatments, evidence is also emerging that it has
substantial antibacterial effects at high concentrations against pathogenic strains. Administering
5-FU to patients orally often results in inflammation and ulceration of the oral mucosa
(Vanlancker et al., 2016). Thus, exploring the antibacterial activity of 5-FU using other routes of
drug delivery is key to maximizing its therapeutic potentials.

Figure 5. Chemical Structure of 5-Fluorouracil.
Topical drug delivery is an attractive method for local and systemic treatments and is
commonly used in the treatment of inflammatory conditions like dermatological diseases and
musculoskeletal injuries (Dantas et al., 2016). Topical application has many advantages over the
conventional dosage forms, especially the avoidance of serious systemic adverse effects
(Whitehouse, 2011). Topical drug delivery allows for deeper skin penetration and hence better
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absorption (Glavas-Dodov et al., 2003). Topical administration prevents the metabolism of drug
in the liver, avoids both gastrointestinal disorders and the risks of intravenous therapy, and
avoids the risks associated with the varied conditions of absorption like pH changes, presence of
enzymes, and gastric emptying time (Dantas et al., 2016). This results in an overall increase in
the bioavailability of drugs at the targeted site of action. The main advantage of a topical
delivery system is the avoidance of first pass metabolism. A wide variety of pharmaceutical
dosage forms can be used as a delivery system for topical drugs. The most commonly used
dosage forms include gels, creams, and ointments, followed by sprays and liquid preparations
(Gisby & Bryant, 2000). Formulating drugs as topical gels can increase residence time of the
drug and improve release of the active ingredients which enhance the overall bioavailability of
the drug at the site of action. Challenges associated with the bioavailability of drugs have forced
formulation scientists to explore drug delivery systems that are safe, non-toxic, and will
effectively enhance the release of drugs at the intended site of action.
Chitosan is a naturally occurring compound that is present in the coating of some
mollusks and insects (Escarcega-Galaz et al., 2018). Structurally, chitosan is a linear amino
polysaccharide and is composed of glucosamine and N-acetyl glucosamine units and linked by β
(1–4) glycosidic bonds (Aytekin et al., 2011; Dai et al., 2011; Muxika et al., 2017; Ouyang et al.,
2018) (Figure 3). The presence of nitrogen in the molecular structure of chitosan and its cationic
nature makes the chitosan polymer distinct from other polysaccharides (Bhattarai et al., 2010).
As a natural copolymer, chitosan is commercially derived from chemical deacetylation of
crustacean chitin under strong alkali treatment (Fai et al., 2011; Muxika et al., 2017). Chitosan
and its derivatives have been widely used in the fields of medicine, cosmetics, wound dressing,
and tissue engineering (Muzzarelli et al., 2012) as a suitable polymer for the delivery of active
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ingredients such as drugs, growth factors, stem cells, and peptides (Bhattarai et al., 2010). This is
because chitosan polymers are generally considered to be a biodegradable, biocompatible, nonantigenic, non-toxic, biologically adhesive, antimicrobial and biologically active compound with
hemostatic effect (Dai et al., 2011; Huang & Fu, 2010; Liu et al., 2018). As part of their chemical
characteristics, chitosan materials exhibit a positive charge (at typical wound pH values), filmforming capacities, mild gelation characteristics, and strong wound tissue adhesive properties
(Jayakumar et al., 2011). Clinically, chitosan formulations are used in wound dressing due to its
antibacterial and hemostatic activities (Zhao et al., 2017).
One of the ways to advance knowledge on the industrial use of chitosan formulations is
by investigating its steady and dynamic rheological properties such as flow and deformation.
Despite the numerous studies investigating biomedical application of chitosan, rheological
studies on the polymer are scarce. Therefore, understanding the rheological properties of
commercial chitosan is essential to designing, predicting, and characterizing most of its
biomedical application (Calero et al., 2010). Rheological measurements are helpful to understand
the effect of handling and preparing viscoelastic materials. They also help to assess the damage
caused by heat, oxygen, etc. on the structure of different materials, including polymers. LizardiMendoza et al. (2016) have reported that as the degree of deacetylation of chitosan decreases,
viscosity and other flow properties tend to increase. Therefore, understanding the rheological
changes that happen during phase transition of chitosan in gel formulation is important in its
development and usage as a drug delivery system. Dynamic rheological measurement is useful
for understanding the viscoelastic behavior of gels and pastes while allowing the continuous
measurement of steady properties such as the effect of shear stress, temperature, frequency, and
amplitude on these materials (Bhardwaj et al., 2019). Rheological characteristics help
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formulation scientists to effectively formulate chitosan as either hydrogel, biofilm, nanosphere,
implant coating, etc. Even though the FDA has cleared several chitosan based medical devices
and combination products, including topical wound dressings and wound dressings containing
antimicrobial drugs (Nilsen-Nygaard et al., 2015), rheological studies on the polymer are limited.
Thus, the main objective of this study was to model and study the steady shear
measurements (flow behavior, apparent viscosity), dynamic measurements (oscillation sweep
test of amplitude and frequency) and creep recovery properties of 2% CS gel in order to assess
its potential as a topical drug delivery vehicle. A further goal was to examine the stability and
antimicrobial activity of 2% CS gel formulated with different concentrations of 5-FU in vitro. To
our knowledge, the antimicrobial activity of 5-FU-CS gel has not been previously reported.
MATERIALS AND METHODS
Low molecular weight chitosan powder and pure 5-Flurouracil were obtained from
Sigma Aldrich (Missouri, USA, P 9012-76-4). Methicillin-resistant Staphylococcus aureus,
(MRSA), Strain JE2, methicillin-susceptible S. aureus (MSSA), RN1, NR-46543 (BEI
Resources, NIAID, NIH), and Escherichia coli K-12, Strain DC10B, NR-49804 were obtained
from BEI Resources (NIAID, NIH).
5-FU-Chitosan Gel
Chitosan gel (2% w/w) was prepared by dissolving 2.0 grams of low molecular weight
chitosan powder in 100 ml of 1% acetic acid. This mixture was stirred for 12 hours at room
temperature. 5-Fluorouracil was dissolved in DMSO at a stock concentration of 5mg/mL and
serial dilutions of the following 5-FU-CS gel formulations were prepared: 25μg/mL, 2.5μg/mL,
0.25μg/mL, and 0.025μg/mL.
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RHEOLOGICAL MEASUREMENTS
The rheological properties of chitosan gel (2% w/w) were conducted on a HAAKE
MARS III Rheometer (Thermo Fisher Scientific, Rheology, USA) equipped with a stainless-steel
parallel plate (P35 TiL L1507) probe and 0.5 mm gap, operated through RheoWin Data
Management software. The flow behavior, viscosity, stability, and rheological properties of five
chitosan gel formulations (CS gel control; 25µg 5-FU-CS; 2.5µg 5-FU-CS, 0.25µg 5-FU-CS;
0.025µg 5-FU-CS) were analyzed. An adequate amount of sample was loaded onto the
rheometer plate and excess material was trimmed off. All the measurements were performed at
25°C, and the samples were permitted to equilibrate at this temperature prior to the analysis. All
experiments were conducted in triplicate.
STEADY SHEAR MEASUREMENTS
Flow Behavior and Viscosity
The shear stress was measured over a strain rate range of 0.1 to 200 s-1. To reveal the
time dependent flow behavior, samples were sheared first in ascending and then in descending
(200 to 0.1 s-1) shear order. To analyze flow behavior, the data generated was then fitted to
Ostwald de Waele (Equation 1) and Herschel-Bulkley (Equation 2) models:
Equation 1
ɳ = 𝑲𝑲𝜸𝜸𝜸

𝒏𝒏−𝟏𝟏

Equation 2
𝒏𝒏

𝝉𝝉 = 𝝉𝝉𝟎𝟎 + 𝑲𝑲𝜸𝜸𝜸

where 𝜏𝜏 is the shear stress (Pa), 𝛾𝛾𝛾 is the shear rate (s-1), 𝐾𝐾 is the consistency coefficient

(Pa.sn), n is the flow behavior index (dimensionless), and 𝜏𝜏0 is the yield stress (Pa).
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DYNAMIC MEASUREMENTS
Amplitude Oscillation Stress Sweep
Dynamic rheological measurements are determined either at a controlled strain or
controlled stress conditions, where samples are subjected to oscillatory strain or stress (Bhardwaj
et al., 2019). The amplitude sweep test was performed by applying varying amplitude stress (0.5
to 150 Pa) at a constant frequency of 1 Hz (6.28 rads s-1). Sufficient amounts of each formulation
were loaded onto a P35 TiL L1507 plate, excess material was trimmed, and the linear
viscoelastic region (LVR) was obtained. The power law analysis of storage modulus (G’) and
loss modulus (G”) versus stress was evaluated.
Frequency Oscillation Stress Sweep
For the frequency sweep test, samples were subjected to stepwise increasing frequency
(0.1 to 100 Hz) at a constant stress in the field of LVR obtained from the amplitude sweep test.
Storage modulus (G’) and loss modulus (G”) versus stress was evaluated.
Creep Recovery
Sample was loaded onto a P35 TiL L1507 plate and kept for five minutes for structural
recovery and temperature equilibration (25°C). The sample was then subjected to a constant
shear stress (5 Pa) for 250 seconds. Afterward, the stress was released to allow the sample to
recover for 250 seconds making the total time for creep and recovery 500 seconds. The creep
compliance (J) and final percent recovery (R) (Equation 3) were determined from the creep
recovery curve.
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Equation 3
𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹 (%) = �

𝑱𝑱𝟐𝟐𝟐𝟐𝟐𝟐 − 𝑱𝑱𝟓𝟓𝟓𝟓𝟓𝟓
�
𝑱𝑱𝟐𝟐𝟐𝟐𝟐𝟐

where J250 is creep compliance after 250 seconds and J500 is creep compliance after 500

seconds.

Antimicrobial Activity
The antimicrobial potential of drug-free CS gel, 5-FU, and 5-FU-CS gel formulations
(1.25µg, 1.0µg, 0.75µg, 0.5µg, and 0.25µg) per well were tested against Escherichia coli (E.
coli), methicillin-resistant S. aureus (MRSA), and methicillin-susceptible S. aureus (RN1). The
bacteria cell suspensions were calibrated to 0.5 McFarland standard at 600 nm. To measure the
zone of inhibition, inoculums were streaked on the surface of Muller-Hinton agar (MHA) plates
using a sterile cotton swab and evaluated using the well method. Samples of each formulation
were applied directly into their respective wells and the inoculated plates were incubated at 37oC
for 24 hours. The zones showing complete or partial inhibition were measured and the diameters
of inhibition were recorded in millimeters. The serial dilution method in a 96-well plate format
was used to determine the minimum inhibition concentration (MIC) for each sample, where
vancomycin was used as the positive control. The mean zone of inhibition was recorded for all
test samples (n=3). The results were analyzed using two-way ANOVA followed by Bonferroni's
multiple comparison test (P<0.05) at 95% significance level using Graph Pad Prism software
version 9.0 (Graph Pad Software Inc., San Diego, CA, USA).
CS GEL STABILITY
pH and Conductivity Analysis
The pH and conductivity of CS gel formulations under two temperature conditions, i.e.,
4-8°C (Refrigeration; RF) and 20-25°C (Room Temperature; RT), were determined using a
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digital pH meter (Accumet AB15, Fisherbrand) for a period of three weeks. Glass electrodes
were calibrated, and samples were withdrawn and analyzed weekly. The conductivity
measurements were recorded in millivolts. All samples were recorded in triplicate and average
values ± standard error of the means were calculated. Mean pH and conductivity measurements
for all test samples (n=3) were compared by two-way ANOVA followed by Bonferroni's
multiple comparison test (P<0.05) at 95% significance level using Graph Pad Prism software
version 9.0 (Graph Pad Software Inc., San Diego, CA, USA).
RESULTS
Steady Shear Measurements
Shear stress (τ) versus shear rate (γ̍) flow curves for the control and various 5-FUchitosan gel formulations were analyzed. The data generated were fit to Ostwald de Waele
(Equation 1) and Herschel-Bulkley models (Equation 2) When comparing the two models, the
Ostwald de Waele model was considered as best fit due to the high correlation coefficient
number. High correlation coefficient numbers (R) were obtained for CS, 0.25µg 5-FU-CS and
0.025µg 5-FU-CS, with R values of 0.999, 0.967, and 0.911, respectively. R values for 25µg 5FU-CS and 2.5µg 5-FU-CS were substantially less than that of CS alone.
The flow curve for shear stress versus shear rate obtained from our studies shows that
both CS gel alone and CS gel formulated with the different concentrations of 5-FU were nonNewtonian (Figure 7). The curves show that increasing shear rate resulted in a large increase in
shear stress. The flow curves of Newtonian fluids are known to assume a linear relationship
between shear stress and shear rate which means that they are independent of shear rate.
Conversely, non-Newtonian fluids display a non-linear relation between shear stress and shear
rate, and have a yield stress or viscosity property that is dependent on shear rate as a source of
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deformation. The inverse relationship between shear stress and shear rate was observed for all
CS formulations which confirms that CS gel is non-Newtonian.
The flow behavior index (n) is another parameter that helps to further classify flowing
materials as either shear thinning or shear thickening in the pharmaceutical industry. The flow
behavior index was evaluated for all formulations of 5-FU-CS gel. The flow behavior indexes (n)
obtained for CS gel and 5-FU-CS were all less than 1 using both Herschel-Bulkley and Ostwald
de Waele models (Table 2). Values of ɳ < 1 or moving further away from 1 towards zero indicate
the increase in shear thinning behavior (Bhardwaj et al., 2019). Thus, all CS formulations
possessed shear thinning behavior (Figure 6), which confirms the non-Newtonian flow behavior
seen in (Figure 7).

Sample

Model

Parameters
τ0
K
(Pa)
(Pa.sn)

CS gel

Herschel-Bulkley
Ostwald de Waele

-1.528
N/A

1.603
1.243

0.656
0.700

N/A
26.760

N/A
0.999

25μg 5-FU-CS gel

Herschel-Bulkley
Ostwald de Waele

-1.309
N/A

1.233
0.489

0.682
0.888

N/A
0.273

N/A
0.429

2.5μg 5-FU-CS gel

Herschel-Bulkley
Ostwald de Waele

-0.895
N/A

1.020
0.383

0.710
0.926

N/A
0.402

N/A
0.540

0.25μg 5-FU-CS gel

Herschel-Bulkley
Ostwald de Waele

-0.923
N/A

1.030
0.582

0.704
0.828

N/A
0.046

N/A
0.967

0.025μg 5-FU-CS gel

Herschel-Bulkley
Ostwald de Waele

-1.195
N/A

1.068
0.503

0.691
0.848

N/A
0.091

N/A
0.911

n

χ2

R

Table 2. 5-FU-CS Gel Flow Parameters.
A list of parameters of Ostwald de Waele and Herschel-Bulkley models showing the flow
behavior of formulations of chitosan gel with different concentrations of 5-fluorouracil between
0.1 to 200 1/s. Data are expressed as mean (n=3).
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Figure 6. Flow Comparison of CS Gels.
Chitosan gel flow is compared to flow for 5-FU-Chitosan gel and shows the flow behavior of
chitosan gel compared to different concentrations of 5-FU-CS gel. The graph shows a NonNewtonian flow curve of shear stress (τ) vs shear rate (γ’), at 25 0C, for CS gel (black); 25μg/mL
5-FU-CS (green); 2.5μg/mL 5-FU-CS (blue); 0.25μg/mL 5-FU-CS (brown); 0.025μg/mL 5-FUCS (pink). Data shown here are (n=1) of three trials for all experimental groups.
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Figure 7. Chitosan Gel Apparent Viscosity.
The apparent viscosity of chitosan gel is compared to different concentrations of 5-FU-Chitosan
gel. The results show the shear-thinning property of CS gel (black); 25μg/mL 5-FU-CS (green);
2.5μg/mL 5-FU-CS (blue); 0.25μg/mL 5-FU-CS (brown); 0.025μg/mL 5-FU-CS (pink). The
curves show apparent viscosity (ɳ) decreasing with increasing shear rate (γ’) at a constant speed
of 5 Pa, at 25oC. Data shown here are (n=1) of three trials for all experimental groups.
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Dynamic Measurements
The dynamic properties of CS gel alone and different concentrations of 5-FU-CS gel
were determined by measuring the “storage modulus” (G′) and the “loss modulus” (G′′). Storage
modulus (G′), loss modulus (G″), and tan δ obtained during dynamic testing signify the extent of
elastic character, viscous character, and physical state of the material, respectively. G′ provides
information about energy stored, while G″ reveals energy dissipated by the sample (von BorriesMedrano et al., 2019). Here we show the storage modulus (G’) and the loss modulus (G”) of both
CS gel and 5-FU-CS gels at different concentrations increased after the application of frequency
as the source of deformation (0.1 Hz to 10 Hz, Figure 8). Conversely, G’ and G” of CS and 5FU-CS gels decreased after subjecting the gel to different amplitude (strain), as the source of
deformation (0.1 to 100 Pa), (Figure 9).
Amplitude and frequency sweep tests are used to categorize flowing materials as either
(i) dilute solutions, (ii) concentrated solutions, (iii) weak gel materials, or (iv) strong gel
materials. This is achieved by identifying the linear viscoelastic region (LVE) and analyzing the
loss tangent (δ values), which is the ratio of G’ and G’’ (Mitkari et al., 2010). Rheologically,
weak or viscous gels have δ values greater than 1 (δ > 1), and strong or elastic gels have δ values
less than 1 (δ < 1) (Bhardwaj et al., 2019; von Borries-Medrano et al., 2019). The δ values
obtained for CS gel and 5-FU-CS gels were greater than 1, indicating that our CS formulation
was weak and viscous (Figure 10). This affirms the results obtained in the steady shear
measurements. Studies on gels and gel-like materials show that for strong or fully developed
gels, G′ > G′′, where these properties have the ability to be nearly independent of frequency over
a large frequency range (Douglas, 2018). However, the results obtained for both amplitude and
frequency sweep tests showed that the loss modulus is greater than the storage modulus (G’ <
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G”). This indicates that our formulation is less elastic compared to other gelation materials. For
both the CS gel and the different concentrations of 5-FU-CS, the strain value of 5 Pa was within
the LVE region.
For rheology, the storage modulus (G’) indicates the ability of hydrogels to store
deformation energy, which represents the degree of crosslinking in the material. Therefore, the
higher the degree of crosslinking in a material, the greater the storage modulus due to the
presence of localized particles or molecules that store the deformation energy of the stressed
material over long timescales (Douglas, 2018). An explanation for this result could stem from the
swelling properties of the formulation used in this study.
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a.

b.

c.

d.

e.

Figure 8. Chitosan Gel Storage Modulus and Loss Modulus.
The CS storage and loss modulus is compared to different concentrations of 5-FU-CS gel after
oscillatory deformation of frequency. The results show loss modulus (blue) is greater than
storage modulus (red) for (a) CS gel, (b) 25μg/mL 5-FU-CS, (c) 2.5μg/mL 5-FU-CS. (d)
0.25μg/mL 5-FU-CS, and (e) 0.025μg/mL 5-FU-CS. Data shown here are (n=1) of three trials for
all experimental groups.
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Figure 9. Chitosan Gel Deformation Amplitudes.
Storage modulus and loss modulus of CS and different concentrations of 5-FU-CS gel after
oscillatory deformation of amplitude. The results show the gel-like property of CS gel (black);
25μg/mL 5-FU-CS (green); 2.5μg/mL 5-FU-CS (blue); 0.25μg/mL 5-FU-CS (brown);
0.025μg/mL 5-FU-CS (pink), at 25oC. Data shown here are (n=1) of three trials for all
experimental groups.
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Figure 10. Plot of Tan δ vs Shear Stress (τ).
A plot of tan δ vs shear stress (τ) for CS gel and different concentrations of 5-FU-CS gel after
deformation (amplitude) is shown. The results show the elastic property of CS gel (red);
25μg/mL 5-FU-CS (light green); 2.5μg/mL 5-FU-CS (blue); 0.25μg/mL 5-FU-CS (dark green);
0.025μg/mL 5-FU-CS (orange), at 25oC. Data shown here are (n=1) of three trials for all
experimental groups.
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Creep Recovery
The creep compliance as a function of time for CS gel and different concentrations of 5FU-CS gel was carried out at constant stress of 5 Pa and at a temperature of 25oC. Figure 11
shows the creep response after 250 seconds. The highest creep compliance value was recorded
for 0.25μg 5-FU-CS gel at 20.36 Pa-1, and the lowest response was recorded for 0.025μg 5-FUCS gel at 9.08 Pa-1 (Table 3).
Since lower creep compliance corresponds with higher elasticity (Mitkari et al., 2010), it
could be concluded that of the 5-FU-CS gel formulations studied, 0.025μg 5-FU-CS
demonstrated the most elastic behavior. Unlike the creep compliance measurements, the percent
recovery results for all samples were negligible. The reason for these low recovery values could
stem from the low elasticity of the gel. Higher percent recovery would be expected from highly
elastic materials when subjected to steady deformation. The average apparent viscosity values (ɳ
in Pas) recorded after each formulation were subjected to constant strain for creep compliance
analysis were recorded as follows: CS gel (ɳ= 0.48 Pas), 25μg 5-FU-CS gel (ɳ= 0.39), 2.5μg 5FU-CS gel (ɳ= 0.47), 0.25μg 5-FU-CS gel (ɳ= 0.38), and 0.025μg 5-FU-CS (ɳ= 0.36). For most
polymeric solutions, especially pseudoplastic fluids, apparent viscosity decreases with increasing
shear rate. This is because the long chain molecules in such fluids tend to align with each other at
high shear rates resulting in easier flow (Stanbury et al., 2017).
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Figure 11. Chitosan Gel Creep Recovery.
Creep recovery plot of CS gel and different concentrations of 5-FU-CS gels. The results shown
here are creep compliance (J) for CS gel (black); 25μg/mL 5-FU-CS (green); 2.5μg/mL 5-FU-CS
(blue); 0.25μg/mL 5-FU-CS (brown); 0.025μg/mL 5-FU-CS (pink), after application of shear
stress of 5 Pa, at 25oC. Data shown here are (n=1) of three trials for all experimental groups.

Sample

Parameters
τ
ɳ
(Pa)
(Pas)

γ'
(s-1)

Je
(Pa-1)

G
(Pa)

Creep
Recovery
%

CS gel

5.00

0.48

10.52

19.79

0.05

0.01

25μg 5-FU-CS gel

5.00

0.39

12.77

10.21

0.10

0.05

2.5μg 5-FU-CS gel

5.00

0.47

10.89

16.71

0.09

0.11

0.25μg 5-FU-CS gel

5.00

0.38

13.32

20.36

0.08

0.06

0.025μg 5-FU-CS gel

5.00

0.36

14.12

9.08

1.55

0.11

Table 3. Creep Recovery Parameters.
Parameters of creep analysis of 2% CS gel and 5-FU-CS gel. Data are expressed as mean (n=3).
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Antimicrobial Activity
The antimicrobial potential of CS gel, and 5-FU-CS gel at different concentrations, were
determined by measuring the zone of inhibition and minimum inhibitory concentration (MIC)
against select pathogenic bacteria. Figure 12 shows images of the zone of inhibition for each
formulation against MRSA, RN1 and E. coli after 24 hours of exposure. As seen in Figure 12,
the degree of inhibition observed in this experiment for both formulations and vancomycin
(positive control) were complete. However, unlike the positive control, we observed a double
hallow effect around the zones for MRSA. This double hallow effect could be attributed to the
resistant nature of the bacterial pathogens after 24 hours. Overall, the results suggest that 5-FU
and 5-FU-CS gel have antimicrobial potential compared to CS gel. The average zone of
inhibition measured for 5-FU against MRSA were 29.0, 28.0, 25.0, 22.0, and 15.0 mm at
concentrations of 1.25μg/well, 1.0μg/well, 0.75μg/well, 0.5μg/well, and 0.25μg/well,
respectively (Table 4).
Using the same treatment concentrations, the zone of inhibition recorded for 5-FU-CS gel
were 29.0, 28.0, 25.0, 21.0, and 16.0 mm, respectively (Table 4). The average zones of inhibition
measured for 5-FU against RN1 were 21.0, 20.0, 15.0, 11.0, 0.00 mm at concentrations of
1.25μg/well, 1.0μg/well, 0.75μg/well, 0.5μg/well, and 0.25μg/well, respectively (Table 4). The
zone of inhibition recorded for 5-FU-CS gel at the same concentrations were 21.0, 19.0, 15.0,
11.0, 0.00 mm, respectively (Table 4). Even though chitosan hydrogel is known to exhibit
antimicrobial activities against Gram-positive bacteria (Masood et al., 2019), no zone of
inhibition was recorded with the CS gels used against methicillin-resistant S. aureus (MRSA),
and methicillin-susceptible S. aureus (RN1). Additionally, the CS gels had no effect on Gramnegative E. coli.
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Figure 13 and Figure 14 show the zone of inhibition of 5-FU and 5-FU-CS against
MRSA and RN1. The results also showed that, as the concentration decreases for each treatment
(i.e., from 1.25μg/well to 0.25μg/well), the zone of inhibition significantly decreased (P < 0.05).
Comparing the zone of inhibition at similar concentrations of 5-FU to that of 5-FU-CS gel, there
was no statistically significant difference between values measured against MRSA and RN1,
respectively (Figure 13). However, there was a statistically significant difference when the zone
of inhibition measured against MRSA is compared to that of RN1 (p<0.001). The ability of 5FU-CS gel to induce antimicrobial effects could be due to the poly-cationic property of chitosan
that allows it to interact with negatively charged cell membranes of microorganisms, thus
inducing its antimicrobial effects. Moreover, several accounts have been reported on the effect of
a lower percentage of CS formulation on both Gram-positive and Gram-negative bacteria. For
example, Zheng & Zhu (2003) report that 1% chitosan solution could inhibit both bacteria types
completely. In the same study, it was observed that increasing the MW of chitosan induces
significant antimicrobial effect on E. coli and S. aureus (Zheng & Zhu, 2003).
To further evaluate the antimicrobial activity of 5-FU against common bacterial
infections in diabetic wounds, the minimum inhibitory concentration (MIC) of 5-FU was
assessed. Table 5 shows the MIC for 5-FU and vancomycin against MRSA, RN1, and E. coli
using the serial dilution method. The MIC for 5-FU and vancomycin against MRSA was
0.5μg/mL, and 1.0µg/mL, respectively. The MIC for 5-FU and vancomycin against RN1 was
0.5µg/mL, and 1.0µg/mL, respectively. Unlike MRSA and RN1, the MIC for 5-FU against E.
coli was 8.0µg/mL. No MIC was verified for vancomycin against E. coli. Since vancomycin is
often used as the drug of choice for treating MRSA, extensive studies about its MIC have been
reported. The MIC of vancomycin against MRSA and RN1 was 1.0µg/mL which corresponds
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with the literature. For example, Kshetry et al. (2016) found that the minimal inhibitory
concentrations of vancomycin to 47 strains of MRSA ranged from 0.125µg/mL to 1.0µg/mL. To
our knowledge, there are no reports on the antibacterial activity of 2% CS gel on MRSA in the
literature. Thus, the result obtained here is a novel therapeutic approach for the antimicrobial
potential of 2% CS gel on MRSA. Taken together, our experimental data show that 5-FU and 5FU-CS gel have antimicrobial potential on MRSA and RN1 at low concentrations and E. coli at
high concentrations.
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Species
MRSA

Treatment
(μg/well)

Zone of Inhibition
RN1
5-FU-CS

E. coli

5-FU

5-FU-CS

5-FU

5-FU

5-FU-CS

1.25

29.33±0.33

29.33±0.33

21.33±0.67

20.67±0.33

0.00

0.00

1.0

27.67±0.33

27.67±0.67

19.67±0.33

19.33±0.33

0.00

0.00

0.75

25.00±0.58

24.67±0.33

15.00±0.58

15.33±0.33

0.00

0.00

0.5

21.67±1.20

20.67±0.33

11.33±0.33

10.67±0.33

0.00

0.00

0.25

14.67±0.88

16.00±0.58

0.00±0.00

0.00±0.00

0.00

0.00

Table 4. Zones of Inhibition.
The measurement for the zone of inhibition is recorded for 5-FU and 5-FU- CS gel formulations
at different concentrations against bacterial pathogens. Data are expressed as mean ±SEM (n=3).
Bacterial strains evaluated were methicillin-resistant Staphylococcus aureus (JE2, NR-46543),
methicillin-susceptible S. aureus (RN1), and Escherichia coli (K-12, DC10B, NR-49804).
Compounds tested were 5-fluorouracil (5-FU) and 5-fluorouracil chitosan (5-FU-CS) formulated
with DMSO and chitosan gel, respectively as drug delivery vehicles. Vancomycin was used as a
positive control.

48

a

5-FU-CS

5-FU

1.25

1 μg

1.25

MRSA

1 μg
CS

VAN

0.25

0.75

VAN

0.75

0.25
0.5

0.5 μg

b

MRSA

RN1

1 μg

1.25

RN1

1.25
1 μg
CS

VAN

0.75

0.5 μg

c

VAN

0.75

0.25

0.25

E. coli

1.25
0.25

CS
1.25
0.25

VAN
0.5 μg

0.5

E. coli

VAN
1 μg

1 μg
0.5
0.75

0.75

Figure 12. Antimicrobial Activity of Chitosan Gels.
Petri plates of CS gel, 5-FU, and different concentrations of 5-FU-CS gel were evaluated by the
well method. Vancomycin was used as the positive control. The results shown here are (a)
images of the zone of inhibition after 5-FU and 5-FU-CS gel were exposed to MRSA culture
plate for 24 hours, (b) the zone of inhibition after 5-FU and 5-FU-CS gel were exposed to RN1
culture plate for 24 hours, and (c) the zone of inhibition after 5-FU and 5-FU-CS gel were
exposed to E. coli culture plate for 24 hours. All the experiments were repeated three times.
Zones of inhibition were measured in mm.
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✱
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✱
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0

1.2 1.0 0.
0
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5
c

1.2 1.0 0. 0.
75 50 0.25 Van
0
5
c

5-FU

5-FU-CS gel

Drug Formulation (μg/mL)
Figure 13. Chitosan Gel Antimicrobial Activity on Methicillin-Resistant S. aureus (MRSA).
Zones of inhibition for 5-FU, and different concentrations of 5-FU-CS gel against methicillinresistant Staphylococcus aureus (MRSA). Vancomycin was used as positive control. All
experiments were repeated three times and data expressed are Mean ± SEM (n=3). Data were
analyzed by two-way ANOVA with a post hoc Bonferroni multiple comparisons test. *Denotes a
significant difference between 1.25μg 5-FU vs. different concentrations of 5-FU, and 5-FU-CS
gel, respectively. P<0.05 was considered as statistically significant difference.
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1
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5
c
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Figure 14. Chitosan Gel Antimicrobial Activity on Methicillin-Resistant S. aureus (RN1).
Zones of inhibition for 5-FU, and different concentrations of 5-FU-CS gel against methicillinsusceptible Staphylococcus aureus (RN1). Vancomycin was used as positive control. All
experiments were repeated three times and data expressed are Mean (n=3). Data were analyzed
by two-way ANOVA with a post hoc Bonferroni multiple comparisons test. *Denotes significant
difference between 1.25μg 5-FU vs. different concentrations of 5-FU, and 5-FU-CS gel,
respectively. P<0.05 was considered as statistically significant difference.

51

Species MIC (μg/mL)
Compound
5-FU

MRSA
0.5

RN1
0.5

E. coli
8.0

Vancomycin

1

1.0

–

Table 5. 5-FU Minimum Inhibitory Concentration (MIC).
Minimum Inhibitory Concentration (MIC) of 5-FU against methicillin-resistant Staphylococcus
aureus (JE2, NR-46543), methicillin-susceptible S. aureus (RN1), and Escherichia coli (K-12,
DC10B, NR-49804). The test compound was 5-fluorouracil (5-FU) and vancomycin was used as
a positive control.
pH and Conductivity Analysis
pH is an important physiochemical factor that influences metabolic processes and
immune function, especially in the micro-compartments of the stratum corneum. This highlights
the importance of analyzing absolute pH measurements in topical formulations as part of quality
criteria for optimized preparations (Wohlrab & Gebert, 2018). In this study, all CS formulations
were stored at different storage conditions for three weeks and stability indicators such as pH,
conductivity, and change in color were assessed. The stability test for each CS formulation was
carried out at room temperature (RT) (20-25oC) and refrigeration temperature (4-8oC). The
average pH and conductivity measurements obtained at storage conditions are shown in Table 6
and Table 7, respectively.
There was no change in color in CS gel or all 5-FU-CS gel formulations at the end of the
experimental period, indicating the physical stability of the vehicle. The average conductivity of
CS gel and all formulations of 5-FU-CS gel were in the range of 140 to 143 mV, with significant
fluctuations weekly (Figure 15). However, comparing the conductivity values for formulations
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stored at RT to those stored at RF shows no substantial differences at different time points
(Figure 16). The results obtained for pH measurements for CS gel and 5-FU-CS gels
significantly increased each week (i.e., week 0 vs. week 1; week 0 vs week 2; week 0 vs week 3)
after storage at 20-25oC (p < 0.05, Figure 17A). Similarly, the pH values significantly increased
each week after storage at 4-8oC (p < 0.05, Figure 17B). Comparing pH measurements for each
formulation at the respective temperatures (RT vs RF), showed that there was a significant
difference in pH values for 25μg/mL 5-FU-CS gel (during week 3), 2.5μg/mL 5-FU-CS gel
(during week 2), and 0.25μg/mL 5-FU-CS gel (during weeks 1-3), Figure 18A-E. Overall, the
average pH values of CS gel and 5-FU-CS gels formulations were in the range of 4.45 to 4.57
after three weeks of storage at 20-25oC and 4-8oC, respectively. This was expected because CS
gels were formulated with 2% acetic acid. The physiological pH of the stratum corneum is within
4.1 to 5.8 (Proksch, 2018); thus, our gel formulation is unlikely to cause skin irritation, making it
a desirable topical vehicle. In addition, performing stability tests of our chitosan gels provide
reliable evidence on the life cycle or shelf life of our chitosan gel when subjected to different
environmental factors such as temperature changes over a period of time (Szymanska &
Winnicka, 2015). Studies on CS showed that exposure to elevated temperatures (40°C) caused a
significant loss of moisture (dehydration of chitosan powder), which resulted in a decrease in
hardness and mechanical tablet strength (Viljoen et al., 2014). Therefore, understanding the
impact of varied temperatures on CS gel is necessary for its application as a topical delivery
system.
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Weeks

CS gel
pH Conductivity

25μg/mL 5-FU-CS
pH Conductivity

2.5μg/mL 5-FU-CS
pH Conductivity

0.25μg/mL5-FU-CS
pH Conductivity

0.025μg/mL 5-FU-CS
pH Conductivity

0

4.45±0.00

141.0

4.45±0.00

141.0

4.45±0.00

142.0

4.45±0.00

143.0

4.45±0.00

143.0

1

4.53±0.00

141.0

4.54±0.00

139.7

4.51±0.01

141.0

4.52±0.00

141.0

4.52±0.00

141.0

2

4.54±0.01

141.7

4.53±0.00

142.0

4.52±0.00

143.0

4.52±0.01

142.7

4.53±0.00

142.0

3

4.57±0.02

140.3

4.57±0.01

139.7

4.56±0.01

141.0

4.55±0.01

141.0

4.56±0.00

141.0

Table 6. Chitosan Gel pH and Conductivity at Room Temperature.
Stability test of CS gel formulation at room temperature showing conductivity and pH
measurements for three weeks. Data expressed as mean ±SD (n=3).

Weeks

CS gel
pH Conductivity

25μg/mL 5-FU-CS
pH Conductivity

2.5μg/mL 5-FU-CS
pH Conductivity

0.25μg/mL5-FU-CS
pH Conductivity

0.025μg/mL 5-FU-CS
pH Conductivity

0

4.45±0.00

141.0

4.45±0.00

141.0

4.45±0.00

142.0

4.45±0.00

143.0

4.45±0.00

143.0

1

4.54±0.00

140.0

4.54±0.00

140.0

4.51±0.00

141.0

4.53±0.00

140.0

4.52±0.00

141.0

2

4.55±0.00

141.0

4.55±0.00

141.0

4.54±0.01

141.0

4.56±0.01

140.0

4.53±0.00

141.0

3

4.57±0.01

140.0

4.57±0.00

140.0

4.56±0.00

140.7

4.57±0.00

140.0

4.56±0.00

140.0

Table 7. Chitosan Gel pH and Conductivity at Refrigerated Temperature.
Stability test of CS gel formulation at refrigerated temperatures showing conductivity and pH
measurements for three weeks. Data expressed as mean ±SD (n=3).
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A. Stability of CS

B. Stability of 25ug 5-FU-CS

CS RF

142
✱

141
140
139

143

CS RT

0

1

2

3

Conductivity (mV)

Conductivity (mV)

143

25ug 5-FU-CS RT

✱

142

25ug 5-FU-CS RF

141
140
139
138

Time (Weeks)

0

1

2

3

Time (Weeks)

Figure 15. Chitosan Gel Conductivity after Long-Term Storage.
Conductivity measurements after long-term storage at room temperature (RT), 20-25oC and
refrigeration temperature, 4-8oC for three weeks. The results are (A) weekly conductivity
measurements for CS gel at RT vs RF, and (B) weekly conductivity measurements for 25ug 5FU-CS gel at RT vs RF. All values are expressed as Mean ± SEM at 95% confidence intervals.
Data were analyzed by two-way ANOVA with a post hoc Sidak’s multiple comparisons test.
*Denotes significant difference between CS RT vs CS RF; and 25μg 5-FU-CS RT vs. 25μg 5FU-CS RF, respectively. P<0.05 was considered as statistically significant.
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A.
2.5ug 5-FU-CS RT

✱

143

2.5ug 5-FU-CS RF

142
141
140
139

144
Conductivity (mV)

Conductivity (mV)

144

1

2

3

Conductivity (mV)

0.25ug 5-FU-CS RT
0.25ug 5-FU-CS RF

142
141
140
0

1

2

3

Time (Weeks)
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Figure 16. Chitosan Gel Conductivity at Different Temperatures.
Conductivity of CS gel formulation was measured at room temperature (RT) 20-25oC and
refrigeration temperature 4-8oC after three weeks. The results show (A) weekly conductivity
measurements for 2.5ug 5-FU-CS gel at RT vs RF, (B) weekly conductivity measurements for
0.25ug 5-FU-CS gel at RT vs RF, and (C) weekly conductivity measurement for 0.025ug 5-FUCS gel. All values are expressed as Mean ± SEM at 95% confidence intervals. Data were
analyzed by two-way ANOVA with a post hoc Sidak’s multiple comparisons test. *Denotes
significant difference between 2.5μg 5-FU-CS RT vs 2.5μg 5-FU-CS RF; 0.25μg 5-FU-CS RT
vs 0.25μg 5-FU-CS RF; and 0.025μg 5-FU-CS RT vs 0.025μg 5-FU-CS RF, respectively.
P<0.05 was considered as statistically significant.
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Figure 17. Stability Tests Comparing pH Measurement of CS Gel Formulation.
pH measurement of CS formulation after three weeks storage at room temperature and
refrigeration. Results show (A) weekly pH measurements of samples after storage at room
temperature (20-25oC), and (B) weekly pH measurements of samples after storage at
refrigeration temperature (4-8oC). All the pH measurements were recorded three times per week.
All values are expressed as Mean ± SEM with 95% confidence intervals. Data were analyzed by
two-way ANOVA with a post hoc Sidak’s multiple comparisons test. P<0.05 was considered as
statistically significant.
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Figure 18. pH Analysis at Room Temperature (RT), 20-25oC and Refrigeration (RF), 48oC.
The results show (A) pH measurements for CS gel at RT vs RF, (B) pH measurements for 25ug
5-FU-CS gel at RT vs RF, (C) pH measurements for 2.5ug 5-FU-CS gel at RT vs RF, (D) weekly
pH measurements for 0.25ug 5-FU-CS gel at RT vs RF, and (E) pH measurements for 0.025ug
5-FU-CS gel at RT vs RF. All values (n=3) are expressed as Mean ± SEM with 95% confidence
intervals. Data were analyzed by two-way ANOVA with a post hoc Sidak’s multiple
comparisons test. *Denotes significant difference between 25μg 5-FU-CS RT vs 25μg 5-FU-CS
RF; 2.5μg 5-FU-CS RT vs 2.5μg 5-FU-CS RF; 0.25μg 5-FU-CS RT vs 0.25μg 5-FU-CS RF; and
0.025μg 5-FU-CS RT vs 0.025μg 5-FU-CS RF, respectively. P<0.05 was considered as
statistically significant.
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DISCUSSION
Delivering drugs to the topical route is an attractive method for both local and systemic
treatments (Dantas et al., 2016), with many advantages over other routes. Specifically, topical
drug delivery allows for deeper skin penetration, better absorption, and avoidance of serious
systemic adverse drug effects (Glavas-Dodov et al., 2003; Whitehouse, 2011). Topical
administration prevents the metabolism of drugs in the liver, avoids both gastrointestinal
disorders and risks of intravenous therapy, and avoids risks associated with the varied conditions
of absorption (Dantas et al., 2016). This is most often characterized by the overall increase in the
bioavailability of drugs at the targeted site of action. Issues pertaining to the bioavailability of
drugs at the active site have led formulation scientists to explore topical formulations such
creams, gels, and ointments, with the goal of increasing residence time. In light of this notion,
several studies are exploring natural polymers due to their non-toxic and biodegradable nature. In
this study, topical formulations of chitosan gels were formulated, and their rheological properties
evaluated.
Chitosan is a natural polymer that is known to exhibit biodegradable, biocompatible, and
non-toxic properties (Dai et al., 2011; Huang & Fu, 2010; Liu et al., 2018). As part of their
chemical characteristics, chitosan materials exhibit a positive charge, film-forming capacities,
mild gelation characteristics, and strong wound tissue adhesive properties (Jayakumar et al.,
2011). Chitosan formulations are used in wound dressing due to its biological adhesiveness,
antimicrobial, and hemostatic activities (Zhao et al., 2017). To investigate the inherent wound
healing effect of CS and 5-FU-CS gel, rheological properties such as steady shear measurements
and dynamic measurements of CS gel were analyzed. Results obtained from our studies show
that CS gel demonstrates non-Newtonian flow behavior with weak viscoelastic properties. One
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of the true marks of non-Newtonian flow materials is the flow behavior index, where values less
than one indicate shear thinning behavior (Bhardwaj et al., 2019). As seen throughout our
rheological studies, CS gel demonstrates shear thinning behavior.
In rheological studies, parameters such as storage modulus (G′), loss modulus (G″) and
tangent δ provide information pertaining to the extent of elasticity, viscosity, and physical state
of the material. For example, G′ gives information about energy stored by the material, G″
reveals energy dissipated by the sample, and loss tangent (δ values) is the ratio of G’ and G’’
(von Borries-Medrano et al., 2019). Rheologically weak or viscous gels have δ values greater
than 1 (δ > 1), and strong or elastic gels have δ values less than 1 (δ < 1) (Bhardwaj et al., 2019;
von Borries-Medrano et al., 2019). Here we find the δ values obtained for CS gel and 5-FU-CS
gels were all greater than 1, indicating that our CS formulation is a weak and viscous gel. Studies
on gels and gel-like materials show that for strong or fully developed gels, G′ > G′′ these
properties have the ability to be nearly independent of frequency over a large frequency range
(Douglas, 2018). However, the results obtained for both amplitude and frequency sweep tests
showed that the loss modulus is greater than the storage modulus (G’ < G”). This indicates that
our formulation is less elastic compared to other gelation materials.
5-FU is known to have an antibacterial effect at high concentrations, but its effect at
physiologically relevant concentrations is still underexplored (Vanlancker et al., 2016). We show
that at low concentrations (0.025μg/mL), there is antimicrobial activity of 5-FU against
pathogenic bacterium such as methicillin-resistant S. aureus (MRSA) and methicillin-susceptible
S. aureus (RN1), and at high concentration (8.0μg/mL) against E. coli. Even though MRSA is
known to develop short-term drug resistance to commonly used antibiotics (Deurenberg et al.,
2007), there was complete zone of inhibition after 24 hours exposure to our topically formulated
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5-FU-CS gel, with a minimum inhibition concentration of 1.0μg/mL. Examples of proposed
antimicrobial mechanisms of CS is centered around the formation of polymer membrane of CS
on the surface of the cell which prevents nutrients from reaching the cells or, the ability of lower
MW CS to enter the cell via pervasion to adsorb electronegative substances therein leading to
disturbance of their physiological activities (Zheng & Zhu, 2003). Taken together, the zone of
inhibition and minimum inhibition concentration results demonstrate that our topically
formulated 5-FU-CS gel is potent and effective against these pathogenic bacteria at low
concentrations.
CONCLUSION
In this study, CS gel was formulated with different concentrations of 5-FU and its
rheological properties and antimicrobial activity were analyzed against pathogenic bacteria. It
was shown that CS gel and 5-FU-CS gel formulated demonstrated non-Newtonian properties
with shear thinning flow behavior. Dynamic rheological measurements revealed that the
formulations have weak viscoelastic properties with G’ < G”, and a loss tangent value greater
than 1. However, the gel formulations were fairly stable at both room and refrigeration
temperatures. We also show that 5-FU and 5-FU-CS gels have significant antimicrobial effect
against common bacterial infections such as MRSA and RN1 at low concentrations, and E. coli
at higher concentrations. Understanding viscosity as a property of gels is important in topical
delivery systems. This is because very low viscous products may easily flow from the surface of
application, while extremely high viscous products like creams are challenged with poor
spreading on surface.
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CHAPTER 4
DRUG DELIVERY SYSTEMS: EXPLORING THE THERAPEUTIC EFFECT OF
5-FU CHITOSAN GEL FOR TOPICAL WOUND HEALING UNDER DIABETIC
CONDITIONS.
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ABSTRACT
Background: Diabetes is one of the most prevalent and costly chronic diseases in the United
States. Diabetic wounds are one of the most severe complications of diabetes mellitus and often
require prolonged hospitalization. The relationship between adipose-derived biomarkers,
adipokines, and metabolic disorders have been well studied; however, little is known about the
role of resistin and PPAR-γ in wound healing. Even though natural polymers such as chitosan have
been extensively studied for their wound healing properties, there is no report on the effect of 5fluorouracil (5-FU) formulated chitosan gel in wound healing under diabetic conditions. Methods:
Chitosan gel (2% w/w) was prepared and formulated with different concentrations of 5-FU
(25μg/mL, 2.5μg/mL, 0.25μg/mL, and 0.025μg/mL). Human dermal fibroblast cells (HDFa) were
treated with each formulation for 24 hours in DMEM growth media. An MTT assay was run to
determine the effect of each formulation on cell viability. The scratch wound healing assay was
used to determine cell migration/wound closure and mRNA gene expression was analyzed by RTqPCR. Results: 5-FU and 5-FU-CS gel induced statistically significant dose-dependent effects on
HDFa cell viability. High-glucose media did not impair HDFa cell migration. 5-FU induces dosedependent effect cell migration and adipokine mRNA gene expression in vitro. Drug free CS gel
had no impact on cell migration. Conclusion: The results suggest that 5-FU has an effect on
adipokine expression, and migration of HDFa cells under diabetic conditions, which could be
further explored with the aim of understanding the mechanism involved in this process and any
potential therapeutic effect on diabetic wound healing.
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INTRODUCTION
Diabetes mellitus is a serious disease which is characterized by insufficient insulin
production by the pancreas or the ineffective use of insulin by the body (Fui et al., 2019).
Epidemiologically, diabetes is considered as one of the most costly and prevalent chronic
diseases in the United States (Narayan et al., 2003). Diabetes has become a major public concern
with considerable social, health, and economic consequences globally (Diez & Iglesias, 2003; Qi
et al., 2004). According to World Health Organization, in 2016 alone, diabetes was the direct
cause of death of 1.6 million patients (World Health Organization, 2020). Examples of diabetesrelated complications include cardiovascular disease, stroke, chronic renal failure, peripheral
neuropathy, and diabetic skin wound. Among these complications, diabetic skin wound is the
most frequent cause of hospitalization (Nathan, 1993).
Foot ulceration, an example of diabetic skin wound, is a common complication that
occurs in about 15% of diabetic patients, and often requires prolonged hospitalization for its
management and is a major disease-associated amputations in developed countries (Albert,
2002). The management of diabetic foot ulceration poses a debilitating financial burden on
patients and the health system (Al Odhayani et al., 2017). The mechanisms responsible for
delays in wound healing in diabetic patients are not fully understood. However, factors such as
age, disease state, diet, reactive oxygen species (Bluher & Mantzoros, 2015), and immune state
have been implicated in poor wound healing in diabetic patients (Brem & Tomic-Canic, 2007;
Oguntibeju, 2019). The relationship of adipose-derived biomarkers, adipokines, and metabolic
disorders have been well studied, especially the role of resistin and PPAR-γ in immune system
modulation, inflammation and metabolic syndrome.
The importance of avoiding wound infection during the wound healing process makes
chitosan a suitable material for wound dressings due to its inherent antibacterial activity and
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many other advantages, such as analgesic effect and hemostatic activity (Zhao et al., 2017). Over
the last decade, several therapies such as debridement, negative pressure wound therapy, and
hyperbaric oxygen have been proposed for the treatment and management of diabetic wounds
(Fui et al., 2019). Even though these unconventional treatments have yielded some positive
results, the high cost of managing diabetic wounds in clinical settings, and the challenges posed
by these treatments, have forced scientists to explore other novel therapeutic treatments that
could enhance wound healing in diabetic patients.
Chitosan is a naturally occurring compound that is present in the coating of some
mollusks and insects (Escarcega-Galaz et al., 2018). Chitosan is a conglomerate copolymers of
glucosamine and N-acetyl glucosamine units linked by b-1,4-glycosidic linkages and is generally
considered to be a biodegradable, biocompatible, non-antigenic, non-toxic, biological
adhesiveness, antimicrobial, and biologically active compound with hemostatic effect (Dai et al.,
2011; Huang & Fu, 2010; Liu et al., 2018). The cationic nature of chitosan as well as the
presence of nitrogen in its molecular structure makes the polymer distinct from other
polysaccharides (Bhattarai et al., 2010). Chitosan and its derivatives have been widely used in
the fields of medicine, cosmetics, wound dressing, and tissue engineering (Muzzarelli et al.,
2012) as a suitable polymer for the delivery of active ingredients such as drugs, growth factors,
stem cells, and peptides (Bhattarai et al., 2010). As part of their chemical characteristics,
chitosan materials exhibit a positive charge (at typical wound pH values), film-forming
capacities, mild gelation characteristics, and strong wound tissue adhesive properties (Jayakumar
et al., 2011). Several studies have demonstrated that chitosan has inherent antibacterial activity
and is clinically useful for developing hydrogel wound dressings due to its analgesic effect and
hemostatic activity (Zhao et al., 2017). From their antimicrobial studies of chitosan in solution,
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powders, and edible films, Friedman et al. (2010) showed that low-molecular-weight chitosan at
a pH < 6.0 presents ideal conditions for achieving suitable antimicrobial and antioxidative,
preservative effects in liquid and solid foods.
In this study, we investigated the therapeutic effect of 5-FU-Chitosan gel on wound
healing under diabetic conditions in vitro. Chitosan gel (2% w/w) was prepared in acetic acid
prior to mixing serial dilutions of 5-FU. The flow behaviors of gels were determined by
rheological analysis. Human dermal fibroblast cells were exposed to each formulation and cell
migration was recorded for 24, 48, and 72 hours. It was hypothesized that 5-FU-Chitosan gel
would upregulate resistin and PPAR-γ expression in HDFa cells and enhance wound closures.
MATERIALS AND METHODS
Normal adult primary human dermal fibroblast (HDFa) (ATCC® PCS201012™),
dimethyl sulfoxide (DMSO) (ATCC® 4-X™), fibroblast basal medium, fibroblast growth kit–
low serum, Dulbecco's modified eagle's medium (DMEM), Dulbecco's phosphate buffered saline
(DPBS), penicillin-streptomycin solution, and fetal bovine serum (FBS) were purchased from
American Type Culture Collection. D-(+)-Glucose, ≥99.5% (GC), acetic acid, low molecular
weight chitosan powder, and 5-Fluorouracil powder were obtained from Sigma Aldrich.
5-FU-Chitosan Gel Formulation
Chitosan gel (2% w/w) was prepared by dissolving 2.0 grams of low molecular weight
chitosan powder in 100 mL of 1% acetic acid and stirring for 12 hours at room temperature. The
pH of gel was 4.03. 5-Fluorouracil was dissolved in DMSO at a stock concentration of 5mg/mL
and serial dilutions of the following 5-FU-CS gel formulations were prepared: 25μg/mL,
2.5μg/mL, 0.25μg/mL, and 0.025μg/mL.
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Cell Culture
For all experiments, normal adult primary human dermal fibroblast (HDFa) cells were
grown in fibroblast basal medium supplemented with Low-serum growth Kit. Fetal bovine serum
(2%), 1% penicillin, streptomycin sulfate, 2 Mm L-glutamine, and Dulbecco’s modified eagle
medium (DMEM) containing high D-glucose was used to simulate diabetic conditions. The
growth medium was replaced every two days. The cells were washed with DPBS prior to
treatment with 5-FU and CS gel formulations. The primary fibroblasts were grown in a
humidified incubator at 5% CO2 and 37oC.
Cell Proliferation Assay
HDFa cells were seeded in 6-well plates at a density of 7.92x105 cells/mL and incubated
overnight. The culture medium was modified to simulate diabetic condition as described above.
After 24 hours of incubation, the cells were treated with 1.0 mL of each formulation of 5-FU-CS
gel for 24 hours. Cells were rinsed three times with DPBS and harvested using 0.53 mM
Trypsin-EDTA. The number of cells for each experimental group were counted in a microscopic
counting chamber.
MTT Cell Viability Assay
Viability of HDFa cells after 24 hours exposure to 5-FU and 5-FU-CS gel at different
concentrations (25μg/mL, 2.5μg/mL, 0.25μg/mL, and 0.025μg/mL) was analyzed using a MTT
assay kit. 200 µL of MTT solution was added to 100μL of cell culture and incubated for four
hours in a 96-well plate. 500μL of 10% SDS solution was added to the cell culture to dissolve
the formation of purple formazan crystals and incubated at 37oC for 24 hours. Absorbance values
of the MTT were read at 570 nm and background absorbance was read at 690 nm. The
background absorbance was subtracted from the 570 nm absorbance.
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Wound Healing Assay
Normal adult primary human dermal fibroblasts were seeded in 6-well plates under
standard culture conditions for 24 hours. The culture medium was modified as described
previously. The cells were wounded across the monolayer with a linear scratch using a sterile
pipette tip (p20) to simulate a wound and washed with DPBS to remove any floating cells and
other cellular debris. The simulated wound was treated with 1.0 mL of each formulation as
described above in the absence of mitomycin C. Images of the wound closure and cell migration
were taken using an inverted fluorescent microscope at 24-hour intervals (i.e., D1, D2, D3, etc.)
until complete closure/migration across the wounded area.
Evaluation of RNA Quality
Cellular RNA of 5-FU, CS treated, and control cells were extracted using the RNeasy Kit
as described by the supplier. RNA was eluted in RNase-free water. The RNA concentration and
purity were determined using the NanoDrop1000 Spectrophotometer (NanoDrop Lite,
Wilmington, USA).
cDNA Synthesis
Based on the total RNA concentration, samples were reverse transcribed into first-strand
cDNA using the DC Protein Assay Kit (BioRad, Hercules, CA) as described by the supplier. For
the synthesis, RNA Standard Mix (2X RT Mix, RT Enzyme) and nuclease free water were
utilized in a total volume of 20 µL. The real time reaction was quantified overnight using the
Real Time PCR Software (QuantStudio).
RT-qPCR for mRNA Gene Expression
RT-qPCR was performed using a Touch real-time detection cycler, and TaqMan® Gene
Expression Master Mix (Fisher Scientific, USA) was used for gene expression profiling. 10 µL
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of RNA Master Mix, and 9.0 µL of cDNA sample was added to 1.0 µL of the target gene primer
(Life Technologies), and PCR was quantified overnight. The target gene primers that were
analyzed were Resistin and PPARγ. The threshold frequency (CT) values of the PCR data were
analyzed by comparing it to the house keeping gene (beta actin). Three independent cell culture
experiments were conducted, and RNA was extracted as mentioned above.
Statistical Analysis
Data are reported as mean ± standard error of the mean. Data from the MTT cell viability
assay of experimental groups were compared using two-way ANOVA followed by Sidak’s
multiple comparisons test. mRNA gene expression of experimental groups was compared using
the student’s t test. Statistical analysis and creation of figures were performed with Graph Pad
Prism software version 9.0 (Graph Pad Software Inc., San Diego, CA, USA). For all tests (n=3),
P < 0.05 was considered statistically significant.
RESULTS
MTT Cell Viability
Viability of HDFa cells as a consequence of exposure to CS gel, 5-FU and 5-FU-CS gel
formulations were analyzed using MTT assay with a calorimetric reaction. Results from the
MTT assay show that 5-FU decreased HDFa cell growth after 24 hours exposure (Figure 19).
When we compared 5-FU treated samples to the vehicle (control group), there was a statistically
significant difference in cell growth (P<0.05), as seen in Figure 19. This effect was evidenced by
the gradual increase in relative percent viability values from 67% for 25μg/mL 5-FU-exposed
cells and 73% for 0.025μg/mL 5-FU-exposed cells. Similar to the 5-FU values, results from our
MTT assay indicate that CS gel and 5-FU-CS gel significantly hinder cell viability (P<0.05,
Figure 19). Among the 5-FU-CS treatment groups, cells exposed to 0.025μg/mL 5-FU-CS gel
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had the highest relative percent viability. However, comparing the different concentrations of 5FU to that of 5-FU-CS gel, showed that 5-FU-CS has a significant impact on cell viability after
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Figure 19. HDFa Cell Viability after 5-FU Exposure.
MTT Assay cell viability of HDFa cells after 24 hours exposure to different formulation of
chitosan gel. The results show relative percent viability after exposure to control (vehicle) and 5FU, and vehicle (CS gel) and 5-FU-CS gel. All values are expressed as Mean ± SEM with 95%
confidence intervals. Data were analyzed by two-way ANOVA with a post hoc Sidak’s multiple
comparisons test. *Denotes significant difference between 5-FU (Vehicle) vs. 25μg/mL 5-FU,
2.5μg/mL 5-FU, 0.25μg/mL 5-FU, and 0.025μg/mL 5-FU, respectively. #Denotes significant
difference between 5-FU vs 5-FU-CS: (5-FU) Vehicle vs (5-FU-CS) Vehicle; 25μg/mL 5-FU vs
25μg/mL 5-FU-CS; 2.5μg/mL 5-FU vs 2.5μg/mL 5-FU-CS; 0.25μg/mL 5-FU vs 0.25μg/mL 5FU-CS; and 0.025μg/mL 5-FU vs 0.025μg/mL 5-FU-CS. P<0.05 was considered as statistically
significant.
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HDFa Wound Closure/Migration
Migration of fibroblast is one of the key steps involved in normal wound healing.
Therefore, to investigate the therapeutic effect of topically formulated CS gel and 5-FU on
human dermal fibroblast migration, an in vitro wound-healing assay was performed. The
migratory ability of dermal fibroblast was not impaired in the presence of high glucose media.
As seen in Figure 20, column A (control group), there was full migration of dermal fibroblast
cells across wounded areas after two days. Even though high glucose is implicated as one of the
factors that delay wound healing, exposing dermal fibroblast to high glucose media resulted in
no negative effect on cell migration in vitro.
CS is a well-known biodegradable polymer with several biomedical applications. Here,
we investigated the therapeutic effect of CS gel and different formulations of 5-FU-CS gel on
migration of human dermal fibroblast under high-glucose conditions. Migration was measured
by movement of cells across a wounded area using the scratch assay. The results from our
scratch assay showed a gradual increase in the rate of cell migration from day one to day five
when cells were exposed 25μg/mL and 0.025μg/mL of 5-FU (Figure 20). Comparing the rate of
migration after treatment with 5-FU, results show a dose dependent effect on cell migration.
Cells treated with 0.025μg/mL 5-FU migrated across the wounded area after day three, compared
to those that were exposed to higher concentrations. Conversely, cells that were exposed to 2%
CS gel showed no sign of migration from day one to day five (Figure 20). This was unexpected
because chitosan gel is known to exhibit inherent wound-healing properties. However, this could
be due to the pH of the gel and possible gel-induced changes in osmotic pressure. These results
suggest that the migratory ability of human dermal fibroblast is enhanced by low concentrations
of 5-FU, and significantly impaired by 2% CS gel.
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Figure 20. Effect of 5-FU and CS Gel on HDFa Cell Migration.
HDFa cell migration after treatment with 5-FU and CS gel under diabetic condition at different
time points. The result shown are microscopic images (A) cell migration after exposure to high
glucose media (control), (B) cell migration after exposure to 25μg/mL 5-FU-CS, (C) cell
migration after exposure to 0.025μg/mL 5-FU-CS gel, and (D) cell migration after exposure to
CS gel.
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mRNA Gene Expression
Prolonged high glucose exposure has been implicated in the loss of endothelial cell
integrity and reduced keratinocyte migration and proliferation in both in vivo and in vitro scratch
wound assays (Okonkwo & DiPietro, 2017; Zhu et al., 2011). Therefore, to examine the
therapeutic effect of 5-FU on wound healing, human dermal fibroblast cells were treated with
multiple doses of 5-FU in 2% CS vehicle in the presence of high-glucose media, and mRNA
gene expression of resistin and PPARγ were analyzed. There was a dose-dependent effect of 5FU on resistin and PPARγ gene expression after 24 hours of treatment. Figure 21 shows that
expression of PPARγ increases with decreasing concentration of 5-FU. However, the level of
gene expression was significantly lower than the control group (P<0.05). Similar dose-dependent
effects were recorded for gene expression of resistin. However, there was upregulation of resistin
gene expression after 24 hours exposure to 25μg/mL and 2.5μg/mL 5-FU. This change in gene
expression was not significant but is worth further explorations in different models. Conversely,
there was a statistically significant decreased in resistin gene expression after treatment with
0.25μg/mL 5-FU.
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Figure 21. Effect of 5-FU on HDFa Gene Expression after 24 Hours Exposure.
The result show relative mRNA gene expression of resistin and PPARγ after exposure to control,
25μg/mL 5-FU, 2.5μg/mL 5-FU, 0.25μg/mL 5-FU, and 0.025μg/mL, respectively. All values are
expressed as Mean ± SEM with 95% confidence intervals. Data were analyzed by student’s t
test. **Denotes significant difference in resistin expression for control vs. 0.25μg/mL 5-FU.
##

Denotes significant difference in PPARγ expression for control vs 25μg/mL 5-FU, and control

vs 2.5μg/mL 5-FU. P<0.05 was considered as statistically significant.
DISCUSSION
Normal wound healing involves the repair of connective tissue and is typified by four
complex and overlapping phases that consists of hemostasis, inflammation, proliferation, and
tissue remodeling (Falanga, 2005; Fui et al., 2019; Gonzalez et al., 2016). One of the critical
things in normal wound healing is timing. Especially, the timing of wound re-epithelialization
and fibroblast proliferation (Cam et al., 2020). Even though the mechanisms responsible for the
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delay in wound healing in diabetic patients are not fully understood, several factors have been
implicated in poor wound healing in diabetic patients (Brem & Tomic-Canic, 2007; Oguntibeju,
2019). Evidence suggests high glucose levels are connected to reduced keratinocyte migration
and proliferation in both in vivo and in vitro scratch wound assays (Zhu et al., 2011). However,
in our studies, exposing human dermal fibroblast cells to high-glucose media did not impair in
vitro cell migration.
Cutaneous wounds require a sequential interaction of cell migration and proliferation
from numerous different tissues and cell types. Among these, fibroblasts have been shown to
play critical roles in all phases of wound healing. For example, following skin abrasion or
wounding, fibroblasts are attracted from the edges of the wound or from the bone marrow to
produce chemokines and growth factors that aid in the wound-healing process (Opalenik &
Davidson, 2005). The proliferation and migration of dermal fibroblasts are essential for
cutaneous wound repair because dermal fibroblasts migrate to damaged sites, repopulate the
wound, and remodel fibrin and collagen deposits (Shi et al., 2015). Diabetes is known to have
adverse effects on fibroblast proliferation which is marked by reduced cell migration abilities
(Lamers et al., 2011; Lerman et al., 2003). In this present study, migratory abilities of human
dermal fibroblast were analyzed using an in vitro scratch assay after exposure to CS gel and 5FU. Fibroblast cells demonstrated migratory abilities in a timely manner depicting observations
seen in normal wound healing.
The established relationship between adipokines and obesity-associated diseases such as
T2DM, show that adipokines have an enormous potential to be clinically relevant both as
bioactive markers and as therapeutic compounds (Bluher, 2014; Timar et al., 2014; Xu et al.,
2015). Alterations in adipokine secretion have been implicated in obesity-related disease. For
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example, human recombinant resistin has been shown to stimulate proliferation, stimulate
migration, and enhance capillary-like tube formation by upregulating gene expression of
angiogenesis-promoting factors (Mu et al., 2006). Further studies also show that PPARα controls
the early inflammation phase of healing (Michalik et al., 2001), PPARβ regulates keratinocyte
proliferation, adhesion, and migration (Michalik et al., 2001; Tan et al., 2003; Tan et al., 2004),
and PPARδ participates in promoting fibroblast proliferation (Li et al., 2012) in normal skin
wound healing. In this study, gene expression of resistin and PPARγ were measured in relation
to cell migration/proliferation after exposure to 5-FU and 2% CS gels. We found increased
expression in resistin after exposure to 25μg/mL and 2.5μg/mL 5-FU. However, we found
decreased expression in PPARγ gene after exposure to all the doses of 5-FU. Even though this
result is contradictory to previous studies, there was an overall improvement in cell migration or
wound closure.
CONCLUSION
5-FU was formulated with 2% CS gel at different concentrations and its therapeutic
potentials on in vitro wound healing and effect on adipokine expressions were examined. It was
shown that 5-FU induces a dose-dependent effect on HDFa cell viability, as well as on adipokine
mRNA gene expression of resistin and PPARγ. Exposure of human dermal fibroblast cells with
5-FU resulted in cell migration in a timely fashion compared to exposure to bare CS gel alone.
Therefore, our experimental results suggest 5-FU is beneficial against adipokine expression,
migration of HDFa cells under diabetic conditions, and could be further explored for its potential
therapeutic effect on diabetic wound healing.
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SUMMARY AND FUTURE DIRECTIONS
Diabetic wounds are one of the most severe complications of diabetes mellitus and
clinically difficult to manage. Unfortunately, the mechanisms responsible for the delay in
diabetic wound healing are not fully understood. However, evidence shows that factors such as
high glucose levels and increased expression of pro-inflammatory adipokines reduce migration
of key cells involved in normal wound healing. These initial studies have paved the way for
target drug delivery through topical applications. Delivering drugs via topical routes is
distinguished by many advantages over conventional routes, especially when drugs are
formulated with non-toxic vehicles. Among these non-toxic vehicles, chitosan is a natural
polymer that has gained more interest as a suitable drug delivery vehicle due to its
biodegradable, biocompatible, and biological properties. Thus, in our study, we show rheological
properties of a 2% CS gel is a suitable vehicle for topical drug delivery. This was achieved by
examining the viscoelastic properties of the gel. After identifying the gel-like properties of CS
gel, it was then formulated with different doses of 5-FU with the aim of improving wound
healing in vitro. Results gathered from our studies show that 5-FU has a dose dependent effect
on HDFa cell migration/wound closure and mRNA adipokine expression.
This preliminary finding has created the platform for further exploration of CS gel as a
drug delivery vehicle for in vivo diabetic models. This would involve evaluating rheological
properties of CS gel at different concentrations, investigating the release profile of 5-FU from CS
gel and biofilm, and testing the therapeutic effect of 5-FU CS gel in animal models.
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APPENDIX A: INSTITUTIONAL REVIEW BOARD APPROVAL
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APPENDIX B: LIST OF ABBREVIATIONS
5-FU

5-fluorouracil

bFGF

Basic fibroblast growth factor

CS

Chitosan

DA

Degree of acetylation

DM

Diabetes mellitus

ECM

Extracellular matrix

G’

Storage modulus

G’’

Loss modulus

GDM

Gestational diabetes mellitus

HBOT

Hyperbaric oxygen therapy

HDF

Human dermal fibroblast

J

Creep compliance

LVR

Liner viscoelastic region

MIC

Minimum inhibition concentration

MRSA

Methicillin-resistant Staphylococcus aureus

MW

Molecular weight

n

Flow behavior index

ɳ

Apparent viscosity

Pa

Pascal

PPAR

Peroxisome proliferator-activated receptor

RF

Refrigeration

RT

Room temperature

95

SEM

Standard error of mean

T1DM

Type 1 diabetes mellitus

T2DM

Type 2 diabetes mellitus

TNFα

Tumor necrosis factor alpha

VEGF

Vascular endothelial growth factor

γ’

Shear rate

τ

Shear stress
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